0001079973-20-000991 | 10-Q | XBRL Viewer

Summary of significant accounting policies (Schedule of Expected Amortization of Intangible Assets) (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
2020 (Three months)		$ 203,811
2021		815,242
2022		815,242
2023		815,242
2024		815,242
2025		815,242
Thereafter		5,744,414
Net Balance	$ 16,071,680	$ 817,550

Condensed Consolidated Balance Sheets (unaudited) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 10,488,072	$ 2,708,223
Accounts receivable, net	423,432	567,811
Inventory, net	2,975,060	473,030
Note receivable		2,521,479
Prepaid expenses and other current assets	1,072,364	396,760
Total current assets	14,958,928	6,667,303
Property and equipment, net	3,370,847	130,759
Finance lease right-of-use assets, net	571,329	958,590
Operating lease right-of-use assets	1,373,418	1,043,537
Goodwill	8,057,894	600,814
Intangible assets, net	16,071,680	817,550
Other noncurrent assets	300,744	203,271
Total assets	44,704,840	10,421,824
Current liabilities
Accounts payable	1,240,351	1,056,035
Accrued compensation and benefits	2,003,002	855,994
Accrued liabilities	2,664,581	1,046,661
Deferred revenue	51,622	9,808
Current maturities of long-term debt	1,156,517	373,599
Short-term finance lease liabilities	348,000	579,030
Short-term operating lease liabilities	1,142,435	1,017,414
Total current liabilities	8,606,508	4,938,541
Long-term debt, net	18,159,433	329,456
Long-term finance lease liabilities	76,701	313,263
Long-term operating lease liabilities	554,295	547,225
Derivative liabilities	74,239
Other long-term liabilities	154,716
Total liabilities	27,625,892	6,128,485
Commitments and contingencies (Note 9)
Stockholders' equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at September 30, 2020 and December 31, 2019, respectively
Common stock, $0.01 par value; 50,000,000 shares authorized; 19,799,348 and 5,582,280 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	197,993	55,823
Additional paid-in capital	208,892,463	178,779,814
Accumulated deficit	(193,625,510)	(174,524,983)
Accumulated other comprehensive income (loss)	1,614,002	(17,315)
Total stockholders' equity	17,078,948	4,293,339
Total liabilities and stockholders' equity	$ 44,704,840	$ 10,421,824

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($)	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 4,323	$ 165,396,036	$ (13,093)	$ (162,078,525)	$ 3,308,741
Balance (in shares) at Dec. 31, 2018	432,286
Public offering of common stock and warrants, net of issuance costs	$ 4,500	4,778,009			4,782,509
Public offering of common stock and warrants, net of issuance costs (in shares)	450,000
Stock compensation expense		98,033			98,033
Foreign currency translation			2,826		2,826
Net loss				(3,853,116)	(3,853,116)
Balance at Mar. 31, 2019	$ 8,823	170,272,078	(10,267)	(165,931,641)	4,338,993
Balance (in shares) at Mar. 31, 2019	882,286
Balance at Dec. 31, 2018	$ 4,323	165,396,036	(13,093)	(162,078,525)	3,308,741
Balance (in shares) at Dec. 31, 2018	432,286
Shares issued in business combination
Net loss					(9,928,565)
Balance at Sep. 30, 2019	$ 8,823	170,449,216	(7,919)	(172,007,090)	(1,556,970)
Balance (in shares) at Sep. 30, 2019	882,268
Balance at Mar. 31, 2019	$ 8,823	170,272,078	(10,267)	(165,931,641)	4,338,993
Balance (in shares) at Mar. 31, 2019	882,286
Stock compensation expense		85,971			85,971
Foreign currency translation			(4,950)		(4,950)
Net loss				(2,593,011)	(2,593,011)
Balance at Jun. 30, 2019	$ 8,823	170,358,049	(15,217)	(168,524,652)	1,827,003
Balance (in shares) at Jun. 30, 2019	882,286
Stock compensation expense		91,167			91,167
Share cancellation
Share cancellation, shares	(18)
Foreign currency translation			7,298		7,298
Net loss				(3,482,438)	(3,482,438)
Balance at Sep. 30, 2019	$ 8,823	170,449,216	(7,919)	(172,007,090)	(1,556,970)
Balance (in shares) at Sep. 30, 2019	882,268
Balance at Dec. 31, 2019	$ 55,823	178,779,814	(17,315)	(174,524,983)	4,293,339
Balance (in shares) at Dec. 31, 2019	5,582,280
At the market offering, net of offering costs	$ 28,149	5,449,283			5,477,432
At the market offering, net of offering costs, shares	2,814,934
Common stock warrant exercises	$ 40,710	8,101,290			8,142,000
Common stock warrant exercises, shares	4,071,000
Stock compensation expense		79,740			79,740
Foreign currency translation			39,477		39,477
Net loss				(3,949,294)	(3,949,294)
Balance at Mar. 31, 2020	$ 124,682	192,410,127	22,162	(178,474,277)	14,082,694
Balance (in shares) at Mar. 31, 2020	12,468,214
Balance at Dec. 31, 2019	$ 55,823	178,779,814	(17,315)	(174,524,983)	4,293,339
Balance (in shares) at Dec. 31, 2019	5,582,280
Shares issued in business combination					4,847,417
Net loss					(19,100,527)
Balance at Sep. 30, 2020	$ 197,993	208,892,463	1,614,002	(193,625,510)	17,078,948
Balance (in shares) at Sep. 30, 2020	19,799,348
Balance at Mar. 31, 2020	$ 124,682	192,410,127	22,162	(178,474,277)	14,082,694
Balance (in shares) at Mar. 31, 2020	12,468,214
At the market offering, net of offering costs	$ 27,394	5,870,807			5,898,201
At the market offering, net of offering costs, shares	2,739,442
Shares issued in business combination	$ 20,282	4,827,135			4,847,417
Shares issued in business combination, shares	2,028,208
Value of equity awards assumed in business combination		136,912			136,912
Issuance of RSUs	$ 52	(52)
Issuance of RSUs (in shares)	5,166
Shares issued to settle convertible notes	$ 4,529	875,903			880,432
Shares issued to settle convertible notes (in shares)	452,902
Stock compensation expense		33,587			33,587
Foreign currency translation			324,939		324,939
Net loss				(7,475,638)	(7,475,638)
Balance at Jun. 30, 2020	$ 176,939	204,154,419	347,101	(185,949,915)	18,728,544
Balance (in shares) at Jun. 30, 2020	17,693,932
At the market offering, net of offering costs	$ 15,237	3,591,793			3,607,030
At the market offering, net of offering costs, shares	1,523,663
Common stock warrant exercises	$ 2,700	537,300			540,000
Common stock warrant exercises, shares	270,000
Issuance of RSUs	$ 7	(7)
Issuance of RSUs (in shares)	750
Shares issued to settle convertible notes	$ 3,110	567,255			570,365
Shares issued to settle convertible notes (in shares)	311,003
Stock compensation expense		41,703			41,703
Foreign currency translation			1,266,901		1,266,901
Net loss				(7,675,595)	(7,675,595)
Balance at Sep. 30, 2020	$ 197,993	$ 208,892,463	$ 1,614,002	$ (193,625,510)	$ 17,078,948
Balance (in shares) at Sep. 30, 2020	19,799,348

Stockholders' equity (Warrants to Purchase Shares of Common Stock) (Details) - $ / shares	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of Common Stock Subject to Warrants	763,386	5,111,107
January 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3,955.00
Expiration	2020-01
Shares of Common Stock Subject to Warrants		17
March 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3,955.00
Expiration	2020-03
Shares of Common Stock Subject to Warrants		7
November 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3,955.00
Expiration	2021-11
Shares of Common Stock Subject to Warrants	15	15
December 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3,955.00
Expiration	2021-12
Shares of Common Stock Subject to Warrants	2	2
February 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3,300.00
Expiration	2025-02
Shares of Common Stock Subject to Warrants	451	451
May 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3,300.00
Expiration	2020-05
Shares of Common Stock Subject to Warrants		6,697
May 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 656.20
Expiration	2021-05
Shares of Common Stock Subject to Warrants	9,483	9,483
June 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 656.20
Expiration	2021-05
Shares of Common Stock Subject to Warrants	4,102	4,102
June 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 390.00
Expiration	2022-06
Shares of Common Stock Subject to Warrants	938	938
July 2017 [Member] \| Warrants Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 345.00
Expiration	2022-07
Shares of Common Stock Subject to Warrants	318	318
July 2017 [Member] \| Warrants Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 250.00
Expiration	2022-07
Shares of Common Stock Subject to Warrants	2,501	2,501
July 2017 [Member] \| Warrants Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 212.60
Expiration	2022-07
Shares of Common Stock Subject to Warrants	50,006	50,006
February 2018 [Member] \| Warrants Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 81.25
Expiration	2023-02
Shares of Common Stock Subject to Warrants	9,232	9,232
February 2018 [Member] \| Warrants Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 65.00
Expiration	2023-02
Shares of Common Stock Subject to Warrants	92,338	92,338
October 2019 [Member] \| Warrants Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 2.00
Expiration	2024-10
Shares of Common Stock Subject to Warrants	359,000	4,700,000
October 2019 [Member] \| Warrants Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 2.60
Expiration	2024-10
Shares of Common Stock Subject to Warrants	235,000	235,000

Organization

9 Months Ended

Sep. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization

Note 1 – Organization

OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. On April 1, 2020, OpGen completed its business combination transaction (the “Transaction”) with Curetis N.V., a public company with limited liability under the laws of the Netherlands (the “Seller” or “Curetis N.V.”), as contemplated by the Implementation Agreement, dated as of September 4, 2019 (the “Implementation Agreement”), by and among the Company, the Seller, and Crystal GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany and wholly-owned subsidiary of the Company (“Purchaser”). Pursuant to the Implementation Agreement, the Purchaser acquired all of the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany (“Curetis GmbH”) and certain other assets and liabilities of the Seller (together, “Curetis”) (see Note 4). References in this report to the “Company” include OpGen and its wholly-owned subsidiaries. The Company’s headquarters are in Gaithersburg, Maryland, and its principal operations are in Gaithersburg, Maryland; Holzgerlingen and Bodelshausen, Germany; and Vienna, Austria. The Company operates in one business segment.

OpGen Overview

OpGen is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company is developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen's current product portfolio includes Unyvero, QuickFISH, PNA FISH, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction as well as the Curetis CE IVD marked SARS CoV-2 test kit. On October 13, 2020, the Company announced its decision to exit the FISH business in its entirety by June 30, 2021 and certain licensing agreements with Life Technologies a subsidiary of ThermoFisher havehas therefore been terminated accordingly.as of such date. The Company's FISH customers and distribution partners have been informed accordingly and last orders are expected to be processed in the coming months. This decision does not meet the criteria for reporting discontinued operations as management, having the authority to approve the action, did not commit to a plan until October 1, 2020.

The focus of OpGen is on its combined broad portfolio of products, which include high impact rapid diagnostics and bioinformatics to interpret AMR genetic data. OpGen will continue to develop and seek FDA and other regulatory clearances or approvals, as applicable, for the Acuitas AMR Gene Panel (Isolates) diagnostic test, Unyvero UTI and IJI products. OpGen will continue to offer the Acuitas AMR Gene Panel (Isolates) and Acuitas Lighthouse Software as well as the Unyvero UTI Panel as RUO products to hospitals, public health departments, clinical laboratories, pharmaceutical companies and contract research organizations, or CROs.

Debt (Schedule of Long-term Debt and Short-term Borrowings) (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Total debt obligations	$ 26,151,573	$ 703,055
Unamortized debt discount	(6,835,623)
Carrying value of debt	19,315,950	703,055
Less current portion	(1,156,517)	(373,599)
Long-term debt	18,159,433	329,456
EIB [Member]
Debt Instrument [Line Items]
Total debt obligations	24,428,437
PPP [Member]
Debt Instrument [Line Items]
Total debt obligations	1,138,983
MGHIF [Member]
Debt Instrument [Line Items]
Total debt obligations	331,292	662,789
Insurance financings [Member]
Debt Instrument [Line Items]
Total debt obligations	$ 252,861	$ 40,266

Stockholders' equity

9 Months Ended

Sep. 30, 2020

Stockholders' Equity Note [Abstract]

Stockholders' equity

Note 8 – Stockholders’ equity

As of September 30, 2020, the Company had 50,000,000 shares of authorized common shares and 19,799,348 shares issued and outstanding, and 10,000,000 shares of authorized preferred shares, of which none were issued or outstanding.

Following receipt of approval from stockholders at a special meeting of stockholders held on January 17, 2018, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, at a ratio of one share for twenty-five shares, and to reduce the authorized shares of common stock from 200,000,000 to 50,000,000 shares. Additionally, following receipt of approval from stockholders at a special meeting of stockholders held on August 22, 2019, the Company filed an additional amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of common stock, at a ratio of one share for twenty shares. All share amounts and per share prices in this Quarterly Report have been adjusted to reflect the reverse stock splits.

On March 29, 2019, the Company closed the March 2019 Public Offering of 450,000 shares of its common stock at a public offering price of $12.00 per share. The offering raised gross proceeds of $5.4 million and net proceeds of approximately $4.8 million.

On October 28, 2019, the Company closed the October 2019 Public Offering of 2,590,170 units at $2.00 per unit and 2,109,830 pre-funded units at $1.99 per pre-funded unit. The offering raised gross proceeds of approximately $9.4 million and net proceeds of approximately $8.3 million. As of September 30, 2020, the 2,109,830 pre-funded warrants issued in the October 2019 Public Offering have been exercised. Additionally, during the nine months ended September 30, 2020, 4,071,000 common warrants were exercised raising net proceeds of approximately $8.1 million.

In connection with the October 2019 Public Offering, the Company issued to its placement agent warrants to purchase 235,000 shares of common stock. The warrants issued to the placement agent have an exercise price of $2.60 per share and are exercisable for five years.

On February 11, 2020, the Company entered into an ATM Agreement with Wainwright, which we amended and restated on November 13, 2020 to add BTIG, LLC pursuant to which the Company may offer and sell from time to time in an “at the market offering,” at its option, up to an aggregate of $22.1 million of shares of the Company's common stock through the sales agents. During the three months ended September 30, 2020, the Company sold 1,523,663 shares of its common stock under the 2020 ATM Offering resulting in aggregate net proceeds to the Company of approximately $3.6 million, and gross proceeds of $3.8 million. During the nine months ended September 30, 2020, the Company sold 7,078,039 shares of its common stock under the 2020 ATM Offering resulting in aggregate net proceeds to the Company of approximately $15.0 million, and gross proceeds of $15.7 million. As of September 30, 2020, remaining availability under the ATM Agreement is $6.4 million.

On April 1, 2020, the Company acquired all of the shares of Curetis GmbH, and certain other assets and liabilities of Curetis N.V., as further described in Notes 1 and 4, and paid, as the sole consideration, 2,028,208 shares of the Company’s common stock to the Seller.

Stock options

In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), pursuant to which the Company’s Board of Directors could grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Company adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan (the “2015 Plan”); the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s initial public offering in May 2015. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 54,200 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of September 30, 2020, 229,533 shares remain available for issuance under the 2015 Plan, which includes 223,291 shares automatically added to the 2015 Plan on January 1, 2020.

On September 30, 2020, the Company held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, stockholders of the Company voted to approve, among other things, a plan under which stock options to purchase an aggregate of 1.3 million shares of the Company’s common stock would be made by the Board of Directors of the Company outside of the stockholder-approved equity incentive plan to its executive officers and non-employee directors (the “2020 Stock Options Plan”). The 2020 Stock Options Plan and the grant made thereunder were approved by the Board of Directors on August 6, 2020, subject to receipt of stockholder approval at the Annual Meeting. The aggregate number of shares of the Company’s common stock authorized for issuance is 1,300,000 shares of common stock and all 1,300,000 million stock options were issued on September 30, 2020. Shares subject to awards granted under the 2020 Stock Options Plan that are forfeited or terminated before being exercised will not be available for re-issuance under the 2020 Stock Options Plan.

Replacement awards

In connection with the acquisition of Curetis, the Company issued equity awards to Curetis employees (“2016 Plan”), consisting of stock options (“replacement awards”) in exchange for their Curetis equity awards. The replacement awards consisted of 134,371 stock options with a weighted average grant date fair value of $1.68. The terms of these replacement awards are substantially similar to the original Curetis equity awards. The fair value of the replacement awards for services rendered through April 1, 2020, the acquisition date, was recognized as a component of the purchase consideration, with the remaining fair value of the replacement awards related to the post-combination services recorded as stock-based compensation over the remaining vesting period.

For the three and nine months ended September 30, 2020 and 2019, the Company recognized share-based compensation expense as follows:

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Cost of services	$	736	$	584	$	2,191	$	1,146
Research and development		12,259		20,175		38,322		55,635
General and administrative		24,100		65,318		102,810		202,696
Sales and marketing		4,608		5,090		11,707		15,694
	$	41,703	$	91,167	$	155,030	$	275,171

No income tax benefit for share-based compensation arrangements was recognized in the condensed consolidated statements of operations and comprehensive loss due to the Company’s net loss position.

The Company granted 1,300,000 options during the three months ended September 30, 2020. During the three months ended September 30, 2020, no options were forfeited and 280 options expired. The Company assumed 134,371 options under the 2016 Plan and granted 1,300,000 stock options during the nine months ended September 30, 2020. During the nine months ended September 30, 2020, 145 options were forfeited and 872 options expired.

The Company had total stock options to acquire 1,443,008 shares of common stock outstanding at September 30, 2020 under all of its equity compensation plans.

Restricted stock units

During the nine months ended September 30, 2020, 5,924 restricted stock units vested and 933 restricted stock units were forfeited. The Company had 8,118 total restricted stock units outstanding at September 30, 2020.

Stock purchase warrants

At September 30, 2020 and December 31, 2019, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at
Issuance		Exercise Price	Expiration	September 30, 2020	December 31, 2019
January 2010	$	3,955.00	January 2020	—	17
March 2010	$	3,955.00	March 2020	—	7
November 2011	$	3,955.00	November 2021	15	15
December 2011	$	3,955.00	December 2021	2	2
February 2015	$	3,300.00	February 2025	451	451
May 2015	$	3,300.00	May 2020	—	6,697
May 2016	$	656.20	May 2021	9,483	9,483
June 2016	$	656.20	May 2021	4,102	4,102
June 2017	$	390.00	June 2022	938	938
July 2017	$	345.00	July 2022	318	318
July 2017	$	250.00	July 2022	2,501	2,501
July 2017	$	212.60	July 2022	50,006	50,006
February 2018	$	81.25	February 2023	9,232	9,232
February 2018	$	65.00	February 2023	92,338	92,338
October 2019	$	2.00	October 2024	359,000	4,700,000
October 2019	$	2.60	October 2024	235,000	235,000
				763,386	5,111,107

The warrants listed above were issued in connection with various debt, equity or development contract agreements.

Commitments and Contingencies (Details) $ in Millions	9 Months Ended
Commitments and Contingencies (Details) $ in Millions	Sep. 30, 2020 USD ($)
Life Technologies Corporation Supply Agreement [Member] \| Quant Studio Five Real Time P C R Systems [Member]
Other Commitments [Line Items]
Agregate purchase commitment	$ 2.8

Revenue from contracts with customers (Tables)

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

Schedule of Revenues by Type of Service

The Company provides diagnostic test products, laboratory services to hospitals, clinical laboratories and other healthcare provider customers, and enters into collaboration agreements with government agencies and healthcare providers. The revenues by type of service consist of the following:

	Three Months Ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Product sales	$	601,562	$	573,035	$	1,569,799	$	1,597,505
Laboratory services		112,892		185		138,884		5,435
Collaboration revenue		342,311		75,000		1,153,400		1,075,000
Total revenue	$	1,056,765	$	648,220	$	2,862,083	$	2,677,940

Revenues by geography are as follows:

	Three Months Ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Domestic	$	309,119	$	597,997	$	1,202,244	$	2,539,519
International		747,646		50,223		1,659,839		138,421
Total revenue	$	1,056,765	$	648,220	$	2,862,083	$	2,677,940

Summary of Changes in Deferred Revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2019	$	9,808
Acquired deferrals from Curetis, net of amounts recognized in the current period		13,270
Revenue recognized in the current period from the amounts in the beginning balance		—
Effect of foreign exchange rates		28,544
Balance at September 30, 2020	$	51,622

Revenue from contracts with customers (Summary of Changes in Deferred Revenue) (Details)	9 Months Ended
	Sep. 30, 2020 USD ($)
Revenue Recognition and Deferred Revenue [Abstract]
Balance at December 31, 2019	$ 9,808
Acquired deferrals from Curetis, net of amounts recognized in the current period	13,270
Revenue recognized in the current period from the amounts in the beginning balance
Effect of foreign exchange rates	28,544
Balance at September 30, 2020	$ 51,622

Business Combination (Tables)

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

Schedule of Components of Purchase Price and Net Assets Acquired

The components of the purchase price and net assets acquired are as follows:

Purchase Price

Number of shares issued to Curetis N.V		2,028,208
Multiplied by the market value per share of OpGen's common stock (i)	$	2.39
Total fair value of common stock issued to Curetis N.V shareholders		4,847,417
Fair value of replacement stock awards related to precombination service (ii)		136,912
Fair value of convertible notes assumed (iii)		1,323,750
Fair value of EIB debt assumed (iv)		15,784,892
Funds advanced to Curetis GmbH under Interim Facility		4,808,712
Cash, cash equivalents, and restricted cash acquired		(1,266,849	)
	$	25,634,834

(i)

The price per share of OpGen’s common stock was based on the closing price as reported on the Nasdaq Capital Market on April 1, 2020.

(ii)

The fair value of the stock options assumed was determined using the Black-Scholes option pricing model.

(iii)

To derive the fair value of the convertible notes, the Company estimated the fair value of the convertible notes with and without the derivative liability using a scenario analysis and Monte Carlo simulation.

(iv)

The fair value of the EIB debt is determined using a discounted cash flow analysis with current applicable rates for similar instruments.

Schedule of Net Assets Acquired

Net Assets Acquired

Assets acquired
Receivables	$	482,876
Inventory		2,022,577
Property and equipment		3,802,431
Right of use assets		1,090,812
Other current assets		585,500
Finite-lived intangible assets
Trade names/trademarks		1,768,000
Customer/distributor relationships		2,362,000
A50 - Developed technology		377,000
Ares - Developed technology		5,345,000
Indefinite-lived intangible assets
A30 - In-process research & development		5,711,000
Goodwill		7,046,535
Liabilities assumed
Accounts payable		(1,168,839	)
Accrued expenses and other current liabilities		(2,016,946	)
Derivative liabilities		(615,831	)
Lease liabilities		(1,108,193	)
Other long-term liabilities		(49,088	)
Net assets acquired	$	25,634,834

Schedule of Unaudited Pro Forma Results

The following unaudited pro forma financial information summarizes the results of operations for the periods indicated as if the Transaction had been completed as of January 1, 2019. Pro forma information primarily reflects adjustments relating to the amortization of intangibles acquired and elimination of interest expense due under the interim facility. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the acquisition occurred as of January 1, 2019 or that may be obtained in the future:

Unaudited pro forma results	Three months ended September 30,			Nine months ended September 30,
	2019			2020			2019
Revenues	$	982,506		$	3,886,834		$	4,245,120
Net loss		(9,204,658	)		(22,340,822	)		(27,067,942	)
Net loss per share		(10.43	)		(1.59	)		(36.31	)

Stockholders' equity (Narrative) (Details) - USD ($)		1 Months Ended			3 Months Ended	9 Months Ended
Stockholders' equity (Narrative) (Details) - USD ($)	Apr. 02, 2020	Sep. 30, 2020	Mar. 29, 2020	Oct. 28, 2019	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Feb. 11, 2020	Dec. 31, 2019	Jan. 17, 2018	Jan. 16, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized		50,000,000			50,000,000	50,000,000			50,000,000	50,000,000	200,000,000
Common stock, shares issued		19,799,348			19,799,348	19,799,348			5,582,280
Common stock, shares outstanding		19,799,348			19,799,348	19,799,348			5,582,280
Preferred stock, shares authorized		10,000,000			10,000,000	10,000,000			10,000,000
Preferred stock, shares issued		0			0	0			0
Preferred stock, shares outstanding		0			0	0			0
Proceeds from issuance of common stock, net of issuance costs						$ 14,982,663	$ 4,782,509
Stock options, forfeited						145
Stock options, outstanding		1,443,008			1,443,008	1,443,008
Stock options, expired					280	872
Number of share options granted					134,371
Stock options, granted					1,300,000	1,300,000
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period						5,924
Share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period						933
Share-based compensation arrangement by share-based payment award, equity instruments other than options, non-vested, outstanding		8,118			8,118	8,118
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized		54,200			54,200	54,200
Share-based compensation arrangement by share-based payment award, description						the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors.
Share-based compensation arrangement by share-based payment award, number of shares available for grant		229,533			229,533	229,533
Share-based compensation arrangement by share-based payment award, common stock percentage						4.00%
Share-based compensation arrangement by share-based payment award, number of additional shares added						223,291
2016 Stock Option Plan [Member] \| Replacement Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options awarded						$ 1.68
Number of share options granted						134,371
Curetis GmbH [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Acquisition of shares	2,028,208
ExecutiveOfficers And Non-Employee Directors [Member] \| 2020 Stock Options Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for future issuance amount		$ 1,300,000			$ 1,300,000	$ 1,300,000
Stock options, granted						1,300,000
Common Stock [Member] \| H.C. Wainwright & Co., LLC [Member] \| 2020 ATM Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues					1,523,663	7,078,039
Proceeds from issuance of common stock, net of issuance costs					$ 3,600,000	$ 15,000,000
Gross proceeds from sale of common stock					$ 3,800,000	15,700,000
Remaining availability under market offering						6,400,000
Common Stock [Member] \| H.C. Wainwright & Co., LLC [Member] \| 2020 ATM Offering [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares available for future issuance amount								$ 22,100,000
March 2019 Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues			450,000
Proceeds from issuance of common stock, net of issuance costs			$ 4,800,000
Gross proceeds from sale of common stock			$ 5,400,000
Shares issued, price per share			$ 12.00
October 2019 Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues				2,590,170
Shares issued, price per share				$ 2.00
Class of warrant or right, exercise price of warrants or rights				$ 2.00
Warrants exercisable period				5 years
October 2019 Public Offering [Member] \| Common Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of common stock, net of issuance costs						$ 8,100,000
Warrants exercised		359,000				4,341,000
October 2019 Public Offering [Member] \| Common Stock [Member] \| Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights				$ 2.60
Warrants exercisable period				5 years
Issuance of common stock warrants to purchase				235,000
October 2019 Public Offering [Member] \| Pre-funded Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues				2,109,830
Shares issued, price per share				$ 1.99
Gross proceeds from sale of common stock and warrants				$ 9,400,000
Net proceeds from sale of common stock and warrants				$ 8,300,000
Class of warrant or right, exercise price of warrants or rights				$ 0.01
Warrants exercised		2,109,830
October 2019 Public Offering [Member] \| Pre Funded Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants exercised				2,109,830

Leases (Schedule of Maturities of Lease Liabilities) (Details) - USD ($)	Sep. 30, 2020	Jan. 02, 2019
Operating
2020	$ 413,498
2021	953,714
2022	205,389
2023	75,533
2024	75,533
Thereafter	44,061
Total lease payments	1,767,728
Less: Interest	(70,998)
Present value of lease liabilities	1,696,730	$ 2,500,000
Finance
2020	120,352
2021	281,914
2022	45,374
2023	3,364
2024	280
Thereafter
Total lease payments	451,284
Less: Interest	(26,583)
Present value of lease liabilities	424,701
Total
2020	533,850
2021	1,235,628
2022	250,763
2023	78,897
2024	75,813
Thereafter	44,061
Total lease payments	2,219,012
Less: Interest	(97,581)
Present value of lease liabilities	$ 2,121,431

Leases (Schedule of Statement of Operations Classification of Lease Costs) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Lease Cost
Total lease costs	$ 473,052	$ 359,821	$ 1,319,247	$ 1,045,883
Operating Expense [Member]
Lease Cost
Operating	332,241	216,368	882,659	655,963
Amortization	125,005	124,749	387,262	329,438
Other Expense [Member]
Lease Cost
Interest expense	$ 15,806	$ 18,704	$ 49,326	$ 60,482

Fair value measurements (Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details)	9 Months Ended
	Sep. 30, 2020 USD ($)
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the beginning of the period
Acquired from Curetis	615,831
Change in Fair Value	(548,008)
Effect of Foreign Exchange Rates	6,416
Balance at the end of the period	74,239
Participation percentage interest liability [Member]
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the beginning of the period
Acquired from Curetis	173,373
Change in Fair Value	(105,550)
Effect of Foreign Exchange Rates	6,416
Balance at the end of the period	74,239
Embedded conversion option liability [Member]
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the beginning of the period
Acquired from Curetis	442,458
Change in Fair Value	(442,458)
Effect of Foreign Exchange Rates
Balance at the end of the period

License agreements, research collaborations and development agreements

9 Months Ended

Sep. 30, 2020

License Agreements Research Collaborations And Development Agreements [Abstract]

License agreements, research collaborations and development agreements

Note 11 – License agreements, research collaborations and development agreements

NYSDOH

In 2018, the Company announced a collaboration with the New York State Department of Health (“DOH”) and ILÚM Health Solutions, LLC (“ILÚM”), a wholly-owned subsidiary of Merck’s Healthcare Services and Solutions division, to develop a state-of-the-art research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide. The Company is working together with DOH’s Wadsworth Center and ILÚM to develop an infectious disease digital health and precision medicine platform that connects healthcare institutions to DOH and uses genomic microbiology for statewide surveillance and control of antimicrobial resistance. As part of the collaboration, the Company received approximately $1.6 million over the 15-month demonstration portion of the project. The demonstration project began in early 2019 and was completed in the first quarter of 2020. The Company began a second-year expansion phase to build on the successes and experience of the first year pilot phase while focusing on accomplishing the goal of this visionary effort to improve patient outcomes and save healthcare dollars by integrating real-time epidemiologic surveillance with rapid delivery of antibiotic resistance results to care-givers via web-based and mobile platforms. The second year contract includes a quarterly retainer-based project fee as well as volume-dependent per test fees for a total contract value of up to $450,000 to OpGen. During the three months ended September 30, 2020 and 2019, the Company recognized $43,000 and $75,000 of revenue related to the contract, respectively. During the nine months ended September 30, 2020 and 2019, the Company recognized $323,000 and $1,075,000 of revenue related to the contract, respectively.

Sandoz

In December 2018, Ares Genetics entered into a service frame agreement with Sandoz International GmbH (“Sandoz”), to leverage Ares Genetics’ database on the genetics of antibiotic resistance, ARESdb, and the ARES Technology Platform for Sandoz’ anti-infective portfolio.

Under the terms of the frame agreement, which has an initial term of 36 months and is currently scheduled to terminate December 13, 2021, Ares Genetics and Sandoz intend to develop a digital anti-infectives platform, combining established microbiology laboratory methods with advanced bioinformatics and artificial intelligence methods to support drug development and life-cycle management. The collaboration, in the short- to mid-term, aims to both rapidly and cost-effectively re-purpose existing antibiotics and design value-added medicines with the objective of expanding indication areas and to overcome antibiotic resistance, in particular with regards to infections with bacteria that has already developed resistance against multiple treatment options. In the longer-term, the platform is expected to inform the development of novel anti-infectives that are less prone to encounter resistance and thereby preserve antibiotics as an effective treatment option.

The agreement covers the first phases of the collaboration with Sandoz and provides certain moderate six-figure R&D funding to Ares Genetics. No milestones or royalties were agreed to as part of this first phase of the collaboration. The agreement may be terminated by Sandoz effective immediately at any time with written notice.

Qiagen

On February 18, 2019, Ares Genetics and Qiagen GmbH, or Qiagen, entered into a strategic licensing agreement for ARESdb and AREStools, in the area of antimicrobial resistance (“AMR”) research. The agreement has a term of 20 years and may be terminated by Qiagen for convenience with 180 days written notice.

Ares Genetics has retained the rights to use ARESdb and AREStools for AMR research, customized bioinformatics services, and for the development of specific AMR assays and applications for the Curetis Group (including Ares Genetics), as well as third parties (e.g. other diagnostics companies or partners in the pharmaceutical industry). As the Qiagen research offering is expected to also enable advanced molecular diagnostic services and products, Qiagen’s customers may obtain a diagnostic use license from Ares Genetics.

Under the terms of the agreement, Qiagen, in exchange for a moderate six figure up-front licensing payment, has received an exclusive RUO license to develop and commercialize general bioinformatics offerings and services for AMR research use only, based on Ares Genetics’ database on the genetics of antimicrobial resistance, ARESdb, as well as on the ARES bioinformatics AMR toolbox, AREStools. Under the agreement, the parties agreed to a mid-single digit percentage royalty rate on Qiagen net sales, which is subject to a minimum royalty rate that steps up upon certain achieved milestones, which is payable to Ares Genetics. The parties also agreed to further modest six figure milestone payments upon certain product launches.

Global leading IVD corporation

On September 16, 2019, Ares Genetics entered into a multi-phase partnership with an undisclosed leading global in vitro diagnostics corporation, or the Partner, to jointly develop diagnostic solutions for infectious disease testing, based on next-generation sequencing, or NGS, technology. Ares Genetics and the Partner also entered into an R&D option agreement for the first phase of the partnership. Ares Genetics received an option fee of approximately $550,000. The initial 10-month term of the R&D collaboration, ended July 13, 2020, with payments excluding the option fee of approximately $1.2 million. The Partner could terminate, at any time and for any reason, with 30 days’ written notice.

In the first phase of the collaboration, which lasted 10 months, the parties have further enriched ARESdb with a focus on certain pathogens relevant in a first, undisclosed infectious disease indication. Additional clinical isolates of such pathogens have been sequenced by Ares Genetics at its recently established NGS laboratory in Vienna, Austria. Based on this enlarged and enriched dataset, Ares Genetics has further developed the algorithms for predictive antibiotic resistance testing for drug/pathogen combinations particularly relevant in the targeted indication to enable NGS-based infectious disease diagnostics.

Under the initial agreement, the Partner funded Ares Genetics’ R&D activities for the genotypic and phenotypic characterization of additional bacterial strains to augment ARESdb and the development of optimized algorithms for predicting antibiotic resistance. Furthermore, in return for the up-front option fee, the Partner obtained a three-month right for first negotiation for an exclusive human clinical diagnostic use license to ARESdb and the ARES Technology Platform. The option can be exercised during the term of the agreement plus three months. Subsequent to September 30, 2020, the Partner exercised the option on October 12, 2020.

The Company recognized approximately $351,000 and $816,000 of revenue related to the contract during the three and nine months ended September 30, 2020, respectively.

FISH License

The Company is a party to one license agreement with Life Technologies to acquire certain patent rights and technologies related to its FISH product line. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. The Company recognized net royalty expense of $62,500 for each of the three months ended September 30, 2020 and 2019. The Company recognized net royalty expense of $187,500 for each of the nine months ended September 30, 2020 and 2019. Annual future minimum royalty fees are $250,000 under this agreement. The Company terminated this license agreement in October 2020 effective as of June 30, 2020 in conjunction with its announced exit of the FISH business in June 2021. The Company will pay a one-time settlement fee of $350,000 and will pay a 10% royalty on the sale of eligible products through June 2021 but is no longer subject to any minimum royalty obligations.

Debt (Narrative) (Details)					1 Months Ended							3 Months Ended				9 Months Ended			12 Months Ended
Debt (Narrative) (Details)	Jul. 10, 2020 EUR (€)	Jul. 09, 2020 EUR (€)	Jul. 14, 2018 USD ($)	Jun. 11, 2018 USD ($)	Jun. 17, 2020 shares	Feb. 24, 2020 $ / shares shares	Jun. 30, 2019 EUR (€)	Jul. 30, 2018 USD ($) shares	Jun. 28, 2017 shares	Apr. 30, 2017 EUR (€)	Jul. 31, 2015 USD ($) $ / shares shares	Sep. 30, 2020 USD ($) $ / shares shares	Jun. 30, 2020 shares	Mar. 31, 2020 shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($) $ / shares shares	Sep. 30, 2020 EUR (€) shares	Sep. 30, 2019 USD ($)	Dec. 31, 2016 EUR (€)	Sep. 30, 2020 EUR (€)	Jul. 10, 2020 USD ($)	Apr. 22, 2020 USD ($)	Dec. 31, 2019 $ / shares	Jun. 30, 2018 EUR (€)
Common Stock And Note Purchase Agreement [Line Items]
Proceeds from issuance of common stock, net of issuance costs																$ 14,982,663		$ 4,782,509
Common stock, par value \| $ / shares												$ 0.01				$ 0.01							$ 0.01
Common Stock [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues \| shares												1,523,663	2,739,442	2,814,934
EIB [Member]
Common Stock And Note Purchase Agreement [Line Items]
Fund drawn period																			36 months
Percentage of participation percentage interest							2.10%
Fair value of debt																					$ 15,800,000
Amount of outstanding borrowings																$ 24,428,000
Deferred interest payable												$ 3,354,000				$ 3,354,000
EIB [Member] \| Euro [Member]
Common Stock And Note Purchase Agreement [Line Items]
Senior unsecured Loan \| €																			€ 25,000,000
Amount of cumulative equity capital raised \| €							€ 15,000,000
Amount of outstanding borrowings \| €																	€ 20,864,740
Deferred interest payable \| €																				€ 2,864,740
EIB debt financing facility [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, interest rate, stated percentage		10.00%
Debt term		5 years
Defer total interest payments \| €	€ 720,000
PPP [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, face amount																						$ 879,630
Percentage of interest accrues																1.00%	1.00%
Interest expense												$ 1,183,927			$ 49,099	$ 2,267,085		$ 142,672
PPP [Member] \| Subsidiary Note [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, face amount																						$ 259,353
MGHIF Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues \| shares											2,273
Shares issued, price per share \| $ / shares											$ 2,200
Proceeds from issuance of common stock, net of issuance costs											$ 5,000,000
Debt instrument, interest rate, stated percentage											8.00%
Debt instrument, face amount											$ 1,000,000
MGHIF Financing Agreement [Member] \| Second Amended and Restated Senior Secured Promissory Note [Member]
Common Stock And Note Purchase Agreement [Line Items]
Accrued and unpaid interest			$ 285,512
Revised and extended the maturity date, payment terms				Six semi-annual payments
Annual payments plus accrued and unpaid interest				$ 166,667
Beginning date of debt maturity				Jan. 02, 2019
Ending date of debt maturity				Jul. 01, 2021
Unamortized debt issuance costs				$ 7,000
MGHIF Financing Agreement [Member] \| Second Amended and Restated Senior Secured Promissory Note [Member] \| Private Placement [Member] \| Common Stock [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues \| shares								7,212
Accrued and unpaid interest								$ 285,512
Accrued and unpaid interest due date								Jul. 14, 2018
Amended and Restated MGHIF Financing Agreement [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, interest rate, stated percentage									10.00%
Debt instrument, extended maturity date									Jul. 14, 2018
Issuance of common stock warrants to purchase \| shares									656
Assignment Agreement [Member] \| Convertible Note [Member]
Common Stock And Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues \| shares												311,003				763,905	763,905
Proceeds from issuance of common stock, net of issuance costs												$ 570,000				$ 1,451,000
Common stock, par value \| $ / shares						$ 0.01
Issuance of convertible notes \| shares					450,000	500,000
Fair value of Convertible notes												$ 1,300,000				$ 1,300,000
Assignment Agreement [Member] \| Convertible Note [Member] \| Euro [Member]
Common Stock And Note Purchase Agreement [Line Items]
Unconverted Convertible Notes \| €																				€ 1,300,000
First Tranche [Member] \| EIB [Member]
Common Stock And Note Purchase Agreement [Line Items]
Debt instrument, interest rate, stated percentage										6.00%
Interst rate										EURIBOR plus 4% payable
First Tranche [Member] \| EIB [Member] \| Euro [Member]
Common Stock And Note Purchase Agreement [Line Items]
Senior unsecured Loan \| €										€ 10,000,000
Second Tranche [Member] \| EIB [Member] \| Euro [Member]
Common Stock And Note Purchase Agreement [Line Items]
Senior unsecured Loan \| €																								€ 3,000,000
Third Tranche [Member] \| EIB [Member] \| Euro [Member]
Common Stock And Note Purchase Agreement [Line Items]
Senior unsecured Loan \| €							5,000,000
Four Tranche [Member] \| EIB [Member] \| Euro [Member]
Common Stock And Note Purchase Agreement [Line Items]
Senior unsecured Loan \| €							€ 5,000,000
OpGen's equity value [Member] \| EIB [Member]
Common Stock And Note Purchase Agreement [Line Items]
Percentage of participation percentage interest							0.30%
Five Tranche [Member] \| EIB [Member] \| Euro [Member]
Common Stock And Note Purchase Agreement [Line Items]
Senior unsecured Loan \| €		€ 5,000,000

Fair value measurements

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair value measurements

Note 6 – Fair value measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

Level 1 - defined as observable inputs such as quoted prices in active markets;

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

For the nine months ended September 30, 2020, the Company has not transferred any assets between fair value measurement levels.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy.

In June 2019, Curetis drew down a third tranche of EUR 5.0 million from the EIB (“European Investment Bank”). In return for EIB waiving the condition precedent of a minimum cumulative equity capital raised of EUR 15 million to disburse this EUR 5.0 million tranche, the parties agreed on a 2.1% participation percentage interest (“PPI”). Upon maturity of the tranche, EIB would be entitled to an additional payment that is equity-linked and equivalent to 2.1% of the then total valuation of Curetis N.V. On July 9, 2020, the Company negotiated an amendment to the EIB debt financing facility. As part of the amendment, the parties adjusted the PPI percentage applicable to the previous EIB tranche of EUR 5.0 million which was funded in June 2019 from its original 2.1% PPI in Curetis N.V.’s equity value upon maturity to a new 0.3% PPI in OpGen’s equity value upon maturity between mid-2024 and mid-2025. This right constitutes an embedded derivative, which is separated and measured at fair value with changes being accounted for through profit or loss. The Company determines the fair value of the derivative using a Monte Carlo simulation model. Using this model, level 3 unobservable inputs include estimated discount rates and estimated risk-free interest rates.

The Company’s convertible debt with YA II PN, LTD (see Note 7) included a conversion feature which constitutes an embedded derivative, which is separated and measured at fair value with subsequent changes being accounted for through profit or loss. The Company determines the fair value of the derivative using a Monte Carlo simulation model. Using this model, level 3 unobservable inputs include estimated volatility rates and estimated risk-free interest rates.

The fair value of level 3 liabilities measured at fair value on a recurring basis for the nine months ended September 30, 2020 was as follows:

Description	Balance at December 31, 2019		Acquired from Curetis		Change in Fair Value			Effect of Foreign Exchange Rates		Balance at September 30, 2020
Participation percentage interest liability	$	—	$	173,373	$	(105,550	)	$	6,416	$	74,239
Embedded conversion option liability		—		442,458		(442,458	)		—		—
Total revenue	$	—	$	615,831	$	(548,008	)	$	6,416	$	74,239

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when a triggering event requires such evaluation. During the nine months ended September 30, 2020, the Company recorded impairment expense of $750,596 related to its intangible assets (see Note 3).

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Summary of significant accounting policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of presentation and consolidation

Basis of presentation and consolidation

The Company has prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. The Company recommends that the following unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s latest Annual Report on Form 10-K. In the opinion of management, all adjustments that are necessary for a fair presentation of the Company’s financial position for the periods presented have been reflected. All adjustments are of a normal, recurring nature, unless otherwise stated. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2019 consolidated balance sheet included herein was derived from the audited consolidated financial statements, but does not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying unaudited condensed consolidated financial statements include the accounts of OpGen and its wholly-owned subsidiaries as of September 30, 2020 including Curetis GmbH and subsidiaries acquired on April 1, 2020; all intercompany transactions and balances have been eliminated.

Foreign currency

Foreign currency

The Company has subsidiaries located in Holzgerlingen, Germany; Vienna, Austria; Copenhagen, Denmark; and Bogota, Colombia, each of which use currencies other than the U.S dollar as their functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in accumulated other comprehensive income (loss), a component of stockholders’ equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive income (loss) at September 30, 2020 and 2019.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss. Unless otherwise noted, all references to “$” or “dollar” refer to the United States dollar.

Use of estimates

Use of estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, stock-based compensation, allowances for doubtful accounts and inventory obsolescence, discount rates used to discount unpaid lease payments to present values, valuation of derivative financial instruments measured at fair value on a recurring basis, deferred tax assets and liabilities and related valuation allowance, determining the fair value of assets acquired and liabilities assumed in business combinations, the estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

Fair value of financial instruments

Financial instruments classified as current assets and liabilities (including cash and cash equivalents, receivables, accounts payable, deferred revenue and short-term notes) are carried at cost, which approximates fair value, because of the short-term maturities of those instruments.

Cash, cash equivalents and restricted cash

Cash, cash equivalents and restricted cash

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the Federal Deposit Insurance Corporation (“FDIC”) insured limit of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

At September 30, 2020 and December 31, 2019, the Company had funds totaling $293,972 and $185,380, respectively, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. These funds are reflected in other noncurrent assets on the accompanying unaudited condensed consolidated balance sheets.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows:

	September 30, 2020		December 31, 2019		September 30, 2019		December 31, 2018
Cash and cash equivalents	$	10,488,072	$	2,708,223	$	626,420	$	4,572,487
Restricted cash		293,972		185,380		185,380		164,720
Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows	$	10,782,044	$	2,893,603	$	811,800	$	4,737,207

Accounts receivable

Accounts receivable

The Company’s accounts receivable result from revenues earned but not yet collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 60 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $20,753 as of September 30, 2020 and December 31, 2019, respectively.

At September 30, 2020, the Company had accounts receivable from two customers which individually represented 17% and 10% of total accounts receivable, respectively. At December 31, 2019, one individual customer represented 44% of total accounts receivable. For the three months ended September 30, 2020, revenue earned from one customer represented 33% of total revenues. For the three months ended September 30, 2019, revenue earned from one customer represented 12% of total revenues. For the nine months ended September 30, 2020, revenue earned from two customers represented 29% and 11% of total revenues, respectively. For the nine months ended September 30, 2019, revenue earned from one customer represented 40% of total revenues.

Inventory

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	September 30, 2020		December 31, 2019
Raw materials and supplies	$	780,054	$	315,542
Work-in-process		141,365		35,080
Finished goods		2,053,641		122,408
Total	$	2,975,060	$	473,030

Inventory includes Unyvero instrument systems, Unyvero cartridges, reagents and components for Unyvero, Acuitas, QuickFISH and PNA FISH products, Curetis SARS CoV-2 test kits, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $412,827 and $92,454 at September 30, 2020 and December 31, 2019, respectively.

Long-lived assets

Long-lived assets

Property and equipment

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. As of the three and nine months ended September 30, 2020 and 2019, the Company determined that its property and equipment was not impaired.

Leases

The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, right-of-use (“ROU”) assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.

Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the effective interest method of recognition. The Company has made certain accounting policy elections whereby the Company (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12 months or less) and (ii) combines lease and non-lease elements of our operating leases.

ROU Assets

ROU assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which the Company can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. In conjunction with adoption of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) (“ASC 842”), the Company determined that the ROU asset associated with its Woburn, Massachusetts office lease may not be recoverable. As a result, the Company recorded an impairment charge of $520,759 during the nine months ended September 30, 2019.

Intangible assets and goodwill

Intangible assets and goodwill as of September 30, 2020 consist of finite-lived and indefinite-lived intangible assets and goodwill.

Finite-lived and indefinite-lived intangible assets

Intangible assets include trademarks, developed technology, In-Process Research & Development, software and customer relationships and consisted of the following as of September 30, 2020 and December 31, 2019:

					September 30, 2020										December 31, 2019
	Subsidiary		Cost		Accumulated Amortization			Impairment			Effect of foreign exchange rates		Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames		AdvanDx	$	461,000	$	(217,413	)	$	(243,587	)		—	$	—	$	(205,887	)	$	255,113
Developed technology		AdvanDx		458,000		(308,526	)		(149,474	)		—		—		(292,170	)		165,830
Customer relationships		AdvanDx		1,094,000		(736,465	)		(357,535	)		—		—		(697,393	)		396,607
Trademarks and tradenames		Curetis		1,768,000		(93,606	)		—			104,096		1,778,490		—			—
Distributor relationships		Curetis		2,362,000		(83,370	)		—			139,067		2,417,697		—			—
A50 - Developed technology		Curetis		377,000		(28,514	)		—			22,197		370,683		—			—
Ares - Developed technology		Curetis		5,345,000		(202,132	)		—			314,697		5,457,565		—			—
A30 - In-Process Research & Development		Curetis		5,711,000		—			—			336,245		6,047,245		—			—
			$	17,576,000	$	(1,670,026	)	$	(750,596	)	$	916,302	$	16,071,680	$	(1,195,450	)	$	817,550

Identifiable intangible assets will be amortized on a straight-line basis over their estimated useful lives. The estimated useful lives of the intangibles are:

		Estimated Useful Life
Trademarks and tradenames		10 years
Customer/distributor relationships		15 years
A50 – Developed technology		7 years
Ares – Developed technology		14 years
A30 – Acquired in-process research & development		Indefinite

Acquired IPR&D represents the fair value assigned to those research and development projects that were acquired in a business combination for which the related products have not received regulatory approval and have no alternative future use. IPR&D is capitalized at its fair value as an indefinite-lived intangible asset, and any development costs incurred after the acquisition are expensed as incurred. Upon achieving regulatory approval or commercial viability for the related product, the indefinite-lived intangible asset is accounted for as a finite-lived asset and is amortized on a straight-line basis over the estimated useful life. If the project is not completed or is terminated or abandoned, the Company may have an impairment related to the IPR&D which is charged to expense. Indefinite-lived intangible assets are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may be impaired. Impairment is calculated as the excess of the asset’s carrying value over its fair value.

The Company reviews the useful lives of intangible assets when events or changes in circumstances occur which may potentially impact the estimated useful life of the intangible assets.

Total amortization expense of intangible assets was $205,026 and $66,954 for the three months ended September 30, 2020 and 2019, respectively. Total amortization expense of intangible assets was $464,689 and $200,862 for the nine months ended September 30, 2020 and 2019, respectively. Expected future amortization of intangible assets is as follows:

Year Ending December 31,
2020 (Three months)	$	203,811
2021		815,242
2022		815,242
2023		815,242
2024		815,242
2025		815,242
Thereafter		5,744,414
Total	$	10,024,435

Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any.

In accordance with ASC 360-10, Property, Plant and Equipment, the Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. During the nine months ended September 30, 2020, events and circumstances indicated the Company’s FISH intangible assets might be impaired. These circumstances included decreased product sales related to the COVID-19 pandemic and the loss of significant customers. Management’s updated estimate of undiscounted cash flows indicated that such carrying amounts were no longer expected to be recovered and that the FISH intangible assets were impaired. The Company’s analysis determined that the fair value of the assets was $0 and the Company recorded an impairment loss of $750,596.

Goodwill

Goodwill represents the excess of the purchase price paid when the Company acquired AdvanDx, Inc. in July 2015 and Curetis in April 2020, over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is not tax deductible in any relevant jurisdictions. The Company’s goodwill balance as of September 30, 2020 and December 31, 2019 was $8,057,894 and $600,814, respectively.

The changes in the carrying amount of goodwill as of September 30, 2020, and since December 31, 2019, were as follows:

Balance as of December 31, 2019	$	600,814
Acquisition of Curetis		7,046,535
Changes in currency translation		410,545
Balance as of September 30, 2020	$	8,057,894

The Company conducts an impairment test of goodwill on an annual basis, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value. During the nine months ended September 30, 2020 and 2019, the Company determined that its goodwill was not impaired.

Revenue recognition

Revenue recognition

The Company derives revenues from (i) the sale of QuickFISH and PNA FISH diagnostic test products, Unyvero Application cartridges, Unyvero Systems, Acuitas AMR Gene Panel RUO test products, (ii) providing laboratory services, and (iii) providing collaboration services including funded software arrangements, and license arrangements.

The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers, (ii) identification of distinct performance obligations in the contract, (iii) determination of contract transaction price, (iv) allocation of contract transaction price to the performance obligations and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation.

The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to our customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services.

The Company defers incremental costs of obtaining a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer. The Company had no material incremental costs to obtain customer contracts in any period presented.

Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.

Research and development costs

Research and development costs

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies, and fees paid to consultants and outside service partners.

Stock-based compensation

Stock-based compensation

Stock-based compensation expense is recognized at fair value. The fair value of stock-based compensation to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. The Company accounts for forfeitures as they occur.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.

Income taxes

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized.

Tax benefits are initially recognized in the condensed consolidated financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss (“NOL”) carryforwards of $188,282,298 at December 31, 2019. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Code. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) stock purchase warrants, and (iii) restricted stock units representing the right to acquire shares of common stock which have been excluded from the computation of diluted loss per share, was 2.2 million shares and 0.2 million shares as of September 30, 2020 and 2019, respectively.

Adopted accounting pronouncements

Adopted accounting pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASC 842”), which amended the existing accounting standards for leases. The new standard requires lessees to record a right-of-use (“ROU”) asset and a corresponding lease liability on the balance sheet (with the exception of short-term leases), whereas under previous accounting standards, the Company’s lease portfolio consisting of operating leases were not recognized on its consolidated balance sheets. The new standard required expanded disclosures regarding leasing arrangements. The new standard was effective for the Company beginning January 1, 2019.

The Company adopted this guidance effective January 1, 2019 using the modified retrospective transition method and the following practical expedients:

The Company did not reassess if any expired or existing contracts are or contain leases.

The Company did not reassess the classification of any expired or existing leases.

Additionally, the Company made ongoing accounting policy elections whereby the Company (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12 months or less) and (ii) combines lease and non-lease elements of our operating leases.

Upon adoption of the new guidance on January 1, 2019, the Company recorded an operating lease ROU asset of approximately $2.2 million (net of existing deferred rent) and recognized a lease liability of approximately $2.5 million.

Prior to the adoption of ASC 842, deferred rent was recorded and amortized to the extent the total minimum rental payments allocated to the period on a straight-line basis exceeded or were less than the cash payments required.

The Company adopted Accounting Standards Update 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"), as of January 1, 2020. ASU 2016-13 requires an entity to measure and recognize expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities with unrealized losses, the standard requires allowances to be recorded through net income instead of directly reducing the amortized cost of the investment under the previous other-than-temporary impairment model. The adoption of this standard did not have a material impact on our condensed consolidated financial statements.

Recently issued accounting standards

The Company has evaluated all other issued and unadopted ASUs and believes the adoption of these standards will not have a material impact on its results of operations, financial position or cash flows.

Debt

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Debt

Note 7 – Debt

The following table summarizes the Company’s long-term debt and short-term borrowings as September 30, 2020 and December 31, 2019:

	September 30, 2020			December 31, 2019
EIB	$	24,428,437		$	—
PPP		1,138,983			—
MGHIF		331,292			662,789
Insurance financings		252,861			40,266
Total debt obligations		26,151,573			703,055
Unamortized debt discount		(6,835,623	)		—
Carrying value of debt		19,315,950			703,055
Less current portion		(1,156,517	)		(373,599	)
Long-term debt	$	18,159,433		$	329,456

MGHIF financing

In July 2015, the Company entered into a Purchase Agreement with MGHIF, pursuant to which MGHIF purchased 2,273 shares of common stock of the Company at $2,200 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to MGHIF an 8% Senior Secured Promissory Note (the “MGHIF Note”) in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. The Company’s obligations under the MGHIF Note are secured by a lien on all of OpGen’s assets excluding the assets of Curetis GmbH, Curetis USA, and Ares Genetics.

On June 28, 2017, the MGHIF Note was amended and restated, and the maturity date of the MGHIF Note was extended by one year to July 14, 2018. As consideration for the agreement to extend the maturity date, the Company issued an amended and restated secured promissory note to MGHIF that (1) increased the interest rate to ten percent (10%) per annum and (2) provided for the issuance of common stock warrants to purchase 656 shares of its common stock to MGHIF.

On June 11, 2018, the Company executed an Allonge to the MGHIF Note. The Allonge provided that accrued and unpaid interest of $285,512 due as of July 14, 2018, the original maturity date, be paid through the issuance of shares of OpGen’s common stock in a private placement transaction. In addition, the Allonge revised and extended the maturity date for payment of the MGHIF Note to six semi-annual payments of $166,667 plus accrued and unpaid interest beginning on January 2, 2019 and ending on July 1, 2021. The Allonge to the MGHIF Note was treated as a debt modification and, as such, the unamortized issuance costs of approximately $7,000 as of June 11, 2018 is deferred and amortized as incremental expense over the term of the MGHIF Note.

On July 30, 2018, the Company issued 7,212 shares of common stock to MGHIF in a private placement transaction in payment of the $285,512 of accrued and unpaid interest due as of July 14, 2018 under the MGHIF Note.

Yorkville Convertible Notes

The Company agreed to assume, as a condition to closing the transactions all of the outstanding convertible notes (the “Convertible Notes”) issued by Curetis N.V. in favor of YA II PN, LTD (“Yorkville”), pursuant to that certain Agreement for the Issuance of and Subscription to Notes Convertible into Shares and Share Subscription Warrants, dated October 2, 2018, by and between Curetis N.V. and Yorkville.

On February 24, 2020, the Company entered into an Assignment of the Agreement for the Issuance of and Subscription to Notes Convertible into Shares (the “Assignment Agreement”) with Curetis N.V. and Yorkville. Pursuant to the Assignment Agreement, upon assumption of the Convertible Notes by the Company, the Convertible Notes ceased to be convertible into shares of Curetis N.V. and are instead convertible into shares of the Company’s common stock, par value $0.01. The Assignment Agreement provided that an amount of 500,000 shares of the Company’s common stock that comprise a portion of the consideration payable by the Company under the Implementation Agreement be reserved for issuance under the Convertible Notes. On June 17, 2020, the Company registered for resale an additional 450,000 shares of Company common stock issuable upon conversion of the Convertible Notes.

At closing of the Transaction, an aggregate amount of €1.3 million of unconverted Convertible Notes was assumed by the Company. The Convertible Notes were measured and recognized at fair value at the acquisition date. The fair value of the Convertible Notes as of the closing of the Transaction was approximately $1.3 million. The resulting debt discount was amortized over the life of the Convertible Notes as an increase in interest expense. During the three months ended September 30, 2020, the Company issued 311,003 shares of common stock in satisfaction of approximately $570,000 of Convertible Notes. During the nine months ended September 30, 2020, the Company issued 763,905 shares of common stock in satisfaction of approximately $1,451,000 of Convertible Notes. As of September 30, 2020, all notes have been converted.

EIB Loan Facility

In 2016, Curetis entered into a contract for an up to €25 million senior, unsecured loan financing facility from the European Investment Bank (“EIB”). The financing is in the first growth capital loan under the European Growth Finance Facility (“EGFF”), launched in November 2016. It is backed by a guarantee from the European Fund for Strategic Investment (“EFSI”), EFSI is an essential pillar of the Investment Plan for Europe (“IPE”), under which the EIB and the European Commission are working as strategic partners to support investments and bring back jobs and growth to Europe.

The funding can be drawn in up to five tranches within 36 months, under the EIB amendment, and each tranche is to be repaid upon maturity five years after draw-down.

In April 2017, Curetis drew down a first tranche of €10 million from this facility. This tranche has a floating interest rate of EURIBOR plus 4% payable after each 12-month-period from the draw-down-date and another additional 6% interest per annum that is deferred and payable at maturity together with the principal. In June 2018, another tranche of €3 million was drawn down. The terms and conditions are analogous to the first one.

In June 2019, Curetis drew down a third tranche of €5 million from the EIB. In line with all prior tranches, the majority of interest is also deferred into the bullet repayment structure upon maturity. In return for EIB waiving the condition precedent of a minimum cumulative equity capital raised of €15 million to disburse this €5 million tranche, the parties agreed on a 2.1% PPI. Upon maturity of the tranche, not before approximately mid-2024 (and no later than mid-2025) EIB would be entitled to an additional payment that is equity-linked and equivalent to 2.1% of the then total valuation of Curetis N.V. As part of the amendment between the Company and EIB on July 9, 2020, the parties adjusted the PPI percentage applicable to the previous EIB tranche of €5 million which was funded in June 2019 from its original 2.1% PPI in Curetis N.V.’s equity value upon maturity to a new 0.3% PPI in OpGen’s equity value upon maturity. This right constitutes an embedded derivative, which is separated and measured at fair value with changes being accounted for through income or loss.

On July 9, 2020, the Company negotiated an amendment to the EIB debt financing facility for an additional €5 million tranche. This additional tranche is earmarked to co-fund R&D programs across several of the platforms and the entire product portfolio of OpGen subsidiaries Curetis and Ares Genetics as it relates to COVID-19.

This additional tranche, which can be drawn down, subject to certain conditions, at Curetis’ option within nine months from the Effective Date of the amendment, will also have a five-year term to maturity from such draw-down date and will accrue interest at a rate of 10% per annum. All interest payments during that five-year term are compounded and become payable only upon maturity of the principal amount of this tranche. The EIB tranche disbursement will become available subject to typical conditions precedent including a pledge of certain Curetis IP rights as security to EIB. All other terms and conditions of the EIB financing contract with Curetis remain unchanged.

Additionally, on July 10, 2020, EIB agreed to defer total interest payments of €720k due in April and June 2020 under the first three tranches of the debt financing facility until December 31, 2020.

The EIB debt was measured and recognized at fair value as of the acquisition date. The fair value of the EIB debt was approximately $15.8 million as of the acquisition date. The resulting debt discount will be amortized over the life of the EIB debt as an increase to interest expense.

As of September 30, 2020, the outstanding borrowings under all tranches were €20,864,740 (approximately USD $24,428,000), including deferred interest payable at maturity of €2,864,740 (approximately USD $3,354,000).

PPP

On April 22, 2020, the Company entered into a Term Note (the “Company Note”) with Silicon Valley Bank (the “Bank”) pursuant to the Paycheck Protection Program (the “PPP”) of the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) administered by the U.S. Small Business Administration. The Company’s wholly-owned subsidiary, Curetis USA Inc. (“Curetis USA” and collectively with the Company, the “Borrowers”), also entered into a Term Note with the Bank (the “Subsidiary Note,” and collectively with the Company Note, the “Notes”). The Notes are dated April 22, 2020. The principal amount of the Company Note is $879,630, and the principal amount of the Subsidiary Note is $259,353.

In accordance with the requirements of the CARES Act, the Borrowers will use the proceeds from the Notes in accordance with the requirements of the PPP to cover certain qualified expenses, including payroll costs, rent and utility costs. Interest accrues on the Notes at the rate of 1.00% per annum. The Borrowers may apply for forgiveness of amounts due under the Notes, in an amount equal to the sum of qualified expenses under the PPP, which include payroll costs, rent obligations, and covered utility payments incurred during the eight weeks following disbursement under the Notes. The Borrowers intend to use the entire proceeds under the Notes for such qualifying expenses. OpGen filed for forgiveness of the Company Note during the three months ended September 30, 2020 and the Subsidiary note subsequent to September 30, 2020.

Subject to any forgiveness under the PPP, the Notes mature two years following the date of issuance of the Notes and include a period for the first six months during which time required payments of interest and principal are deferred. Beginning on the seventh month following the date of the Notes, the Borrowers are required to make 18 monthly payments of principal and interest. The Notes may be prepaid at any time prior to maturity with no prepayment penalties. The Notes provide for customary events of default, including, among others, those relating to breaches of their obligations under the Notes, including a failure to make payments, any bankruptcy or similar proceedings involving the Borrowers, and certain material effects on the Borrowers’ ability to repay the Notes. The Borrowers did not provide any collateral or guarantees for the Notes.

Total interest expense (including amortization of debt discounts and financing fees) on all debt instruments was $1,183,927 and $49,099 for the three months ended September 30, 2020 and 2019, respectively. Total interest expense (including accretion of fair value to face value and amortization of debt discounts and financing fees) on all debt instruments was $2,267,085 and $142,672 for the nine months ended September 30, 2020 and 2019, respectively.

Leases (Schedule of ROU Assets and Lease Liabilities) (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Jan. 02, 2019
ROU Assets:
Operating	$ 1,373,418	$ 1,043,537	$ 2,200,000
Financing	571,329	958,590
Total ROU assets	1,944,747	2,002,127
Current:
Operating	1,142,435	1,017,414
Finance	348,000	579,030
Noncurrent:
Operating	554,295	547,225
Finance	76,701	313,263
Total lease liabilities	$ 2,121,431	$ 2,456,932

Business Combination (Schedule of Net Assets Acquired) (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Asset acquired
Goodwill	$ 8,057,894	$ 600,814
Curetis N.V [Member]
Asset acquired
Receivables	482,876
Inventory	2,022,577
Property and equipment	3,802,431
Right of use assets	1,090,812
Other current assets	585,500
Goodwill	7,046,535
Liabilities assumed
Accounts payable	(1,168,839)
Accrued expenses and other current liabilities	(2,016,946)
Derivative liabilities	(615,831)
Lease liabilities	(1,108,193)
Other long-term liabilities	(49,088)
Net assets acquired	25,634,834
Curetis N.V [Member] \| Trademarks And Trade Names [Member]
Asset acquired
Finite-lived intangible assets	1,768,000
Curetis N.V [Member] \| Customer/distributor relationships [Member]
Asset acquired
Finite-lived intangible assets	2,362,000
Curetis N.V [Member] \| A50 - Developed technology [Member]
Asset acquired
Finite-lived intangible assets	377,000
Curetis N.V [Member] \| Ares - Developed technology [Member]
Asset acquired
Finite-lived intangible assets	5,345,000
Curetis N.V [Member] \| A30 - Acquired in-process research & development [Member]
Asset acquired
Indefinite-lived intangible assets	$ 5,711,000

Summary of significant accounting policies (Schedule of Estimated Useful Lives of Identifiable Intangible Assets) (Details)	9 Months Ended
	Sep. 30, 2020
A50 - Developed technology [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization periods for definite-lived intangible assets acquired	7 years
Ares - Developed technology [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization periods for definite-lived intangible assets acquired	14 years
A30 - Acquired in-process research & development [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization periods for definite-lived intangible assets acquired	Indefinite
Trademarks And Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization periods for definite-lived intangible assets acquired	10 years
Customer/distributor relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-average amortization periods for definite-lived intangible assets acquired	15 years

Revenue from contracts with customers (Narrative) (Details)	Sep. 30, 2020 USD ($)
Revenue from Contract with Customer [Abstract]
Contract assets	$ 22,000

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2020	Nov. 12, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Registrant Name	OPGEN INC
Entity Central Index Key	0001293818
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity File Number	001-37367
Entity Common Stock, Shares Outstanding		20,155,039
Entity Current Reporting Status	Yes
Entity Shell Company	false

Summary of significant accounting policies (Schedule of Reconciliation of Cash Equivalents and Restricted Cash) (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 10,488,072	$ 2,708,223	$ 626,420	$ 4,572,487
Restricted cash	293,972	185,380	185,380	164,720
Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows	$ 10,782,044	$ 2,893,603	$ 811,800	$ 4,737,207

Subsequent Events

9 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

Note 13 – Subsequent Events

Subsequent to September 30, 2020, the Company sold 355,691 shares of its common stock under the 2020 ATM Offering resulting in aggregate net proceeds to the Company of approximately $756,000, and gross proceeds of approximately $782,000. On November 13, 2020, the Company entered into an amended and restated at the market agreement for the 2020 ATM Offering in order to add BTIG as a sales agent in the offering.

On November 10, 2020, the Company entered into a new lease agreement to rent office space in Rockville, Maryland. The lease has an initial term of 10 years and is expected to commence in May 2021. The base rent under the new facility lease agreement is approximately $333,300 for the first year, escalating 2.75% annually thereafter. The lease is subject to additional charges for property management, common area expenses and other costs.

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	19,799,348	5,582,280
Common stock, shares outstanding	19,799,348	5,582,280

Condensed Consolidated Statements of Cash Flows (Parenthetical)	9 Months Ended
	Sep. 30, 2020 USD ($)
Statement of Cash Flows [Abstract]
Cash Acquired From Acquisition	$ 1,266,849

Business Combination (Schedule of Components of Purchase Price and Net Assets Acquired) (Details) - Curetis N.V [Member]

9 Months Ended

Sep. 30, 2020

USD ($)

$ / shares

Purchase Price

Number of shares issued to Curetis N.V | shares

2,028,208

Multiplied by the market value per share of OpGen's common stock | $ / shares

$ 2.39

^[1]

Total fair value of common stock issued to Curetis N.V shareholders

$ 4,847,417

Fair value of replacement stock awards related to precombination service

136,912

^[2]

Fair value of convertible notes assumed

1,323,750

^[3]

Fair value of EIB debt assumed

15,784,892

^[4]

Funds advanced to Curetis GmbH under Interim Facility

4,808,712

Cash, cash equivalents, and restricted cash acquired

(1,266,849)

Purchase Price

$ 25,634,834

[1]	The price per share of OpGen's common stock was based on the closing price as reported on the Nasdaq Capital Market on April 1, 2020.
[2]	The fair value of the stock options assumed was determined using the Black-Scholes option pricing model.
[3]	To derive the fair value of the convertible notes, the Company estimated the fair value of the convertible notes with and without the derivative liability using a scenario analysis and Monte Carlo simulation.
[4]	The fair value of the EIB debt is determined using a discounted cash flow analysis with current applicable rates for similar instruments.

Fair value measurements (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The fair value of level 3 liabilities measured at fair value on a recurring basis for the nine months ended September 30, 2020 was as follows:

Description	Balance at December 31, 2019		Acquired from Curetis		Change in Fair Value			Effect of Foreign Exchange Rates		Balance at September 30, 2020
Participation percentage interest liability	$	—	$	173,373	$	(105,550	)	$	6,416	$	74,239
Embedded conversion option liability		—		442,458		(442,458	)		—		—
Total revenue	$	—	$	615,831	$	(548,008	)	$	6,416	$	74,239

Summary of significant accounting policies (Schedule of Finite-Lived Intangible Assets) (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Cost	$ 17,576,000	$ 17,576,000
Accumulated Amortization	(1,670,026)	(1,195,450)
Impairment	(750,596)
Effect of foreign exchange rates	916,302
Net Balance	16,071,680	817,550
Trademarks And Trade Names [Member] \| AdvanDx [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	461,000	461,000
Accumulated Amortization	(217,413)	(205,887)
Impairment	(243,587)
Effect of foreign exchange rates
Net Balance		255,113
Trademarks And Trade Names [Member] \| Curetis N.V [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,768,000	1,768,000
Accumulated Amortization	(93,606)
Impairment
Effect of foreign exchange rates	104,096
Net Balance	1,778,490
Developed Technology [Member] \| AdvanDx [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	458,000	458,000
Accumulated Amortization	(308,526)	(292,170)
Impairment	(149,474)
Effect of foreign exchange rates
Net Balance		165,830
Customer/distributor relationships [Member] \| AdvanDx [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,094,000	1,094,000
Accumulated Amortization	(736,465)	(697,393)
Impairment	(357,535)
Effect of foreign exchange rates
Net Balance		396,607
Distributor Relationships [Member] \| Curetis N.V [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	2,362,000	2,362,000
Accumulated Amortization	(83,370)
Impairment
Effect of foreign exchange rates	139,067
Net Balance	2,417,697
A50 - Developed technology [Member] \| Curetis N.V [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	377,000	377,000
Accumulated Amortization	(28,514)
Impairment
Effect of foreign exchange rates	22,197
Net Balance	370,683
Ares - Developed technology [Member] \| Curetis N.V [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	5,345,000	5,345,000
Accumulated Amortization	(202,132)
Impairment
Effect of foreign exchange rates	314,697
Net Balance	5,457,565
A30 - Acquired in-process research & development [Member] \| Curetis N.V [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	5,711,000	5,711,000
Accumulated Amortization
Impairment
Effect of foreign exchange rates	336,245
Net Balance	$ 6,047,245

Leases

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Leases

Note 10 – Leases

The following table presents the Company’s ROU assets and lease liabilities as of September 30, 2020 and December 31, 2019:

Lease Classification	September 30, 2020		December 31, 2019
ROU Assets:
Operating	$	1,373,418	$	1,043,537
Financing		571,329		958,590
Total ROU assets	$	1,944,747	$	2,002,127
Liabilities
Current:
Operating	$	1,142,435	$	1,017,414
Finance		348,000		579,030
Noncurrent:
Operating		554,295		547,225
Finance		76,701		313,263
Total lease liabilities	$	2,121,431	$	2,456,932

Maturities of lease liabilities as of September 30, 2020 by fiscal year are as follows:

Maturity of Lease Liabilities		Operating			Finance			Total
	2020	$	413,498		$	120,352		$	533,850
	2021		953,714			281,914			1,235,628
	2022		205,389			45,374			250,763
	2023		75,533			3,364			78,897
	2024		75,533			280			75,813
	Thereafter		44,061			—			44,061
	Total lease payments		1,767,728			451,284			2,219,012
	Less: Interest		(70,998	)		(26,583	)		(97,581	)
	Present value of lease liabilities	$	1,696,730		$	424,701		$	2,121,431

Statement of operations classification of lease costs as of the three and nine months ended September 30, 2020, and 2019 are as follows:

		Three months ended September 30,				Nine months ended September 30,
Lease Cost	Classification	2020		2019		2020		2019
Operating	Operating expenses	$	332,241	$	216,368	$	882,659	$	655,963
Finance:
Amortization	Operating expenses		125,005		124,749		387,262		329,438
Interest expense	Other expenses		15,806		18,704		49,326		60,482
Total lease costs		$	473,052	$	359,821	$	1,319,247	$	1,045,883

Other lease information as of September 30, 2020 is as follows:

Other Information	Total
Weighted average remaining lease term (in years)
Operating leases		2.0
Finance leases		1.1
Weighted average discount rate:
Operating leases		5.9	%
Finance leases		9.7	%

Supplemental cash flow information as of the nine months ended September 30, 2020, and 2019 is as follows:

Supplemental Cash Flow Information	2020		2019
Cash paid for amounts included in the measurement of lease liabilities
Cash used in operating activities
Operating leases	$	882,659	$	655,963
Finance leases	$	45,185	$	60,482
Cash used in financing activities
Finance leases	$	467,593	$	389,501
ROU assets obtained in exchange for lease obligations:
Finance leases	$	—	$	592,014

Debt (Tables)

9 Months Ended

Sep. 30, 2020

Debt Disclosure [Abstract]

Schedule of Long-term Debt and Short-term Borrowings

The following table summarizes the Company’s long-term debt and short-term borrowings as September 30, 2020 and December 31, 2019:

	September 30, 2020			December 31, 2019
EIB	$	24,428,437		$	—
PPP		1,138,983			—
MGHIF		331,292			662,789
Insurance financings		252,861			40,266
Total debt obligations		26,151,573			703,055
Unamortized debt discount		(6,835,623	)		—
Carrying value of debt		19,315,950			703,055
Less current portion		(1,156,517	)		(373,599	)
Long-term debt	$	18,159,433		$	329,456

Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 9 – Commitments and Contingencies

Supply agreements

In June 2017, the Company entered into an agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific (“LTC”), to supply the Company with Thermo Fisher Scientific’s QuantStudio 5 Real-Time PCR Systems (“QuantStudio 5”) to be used to run OpGen’s Acuitas AMR Gene Panel tests. Under the terms of the agreement, the Company must notify LTC of the number of QuantStudio 5s that it commits to purchase in the following quarter. As of September 30, 2020, the Company had acquired twenty-four QuantStudio 5s including none during the nine months ended September 30, 2020. As of September 30, 2020, the Company has not committed to acquiring additional QuantStudio 5s in the next three months.

Curetis places frame-work orders for Unyvero-Systems and for raw materials for its cartridge manufacturing to ensure availability during commercial ramp-up-phase and also to gain volume-scale-effects with regards to purchase prices. Some of the electronic parts used for the production of Unyvero-Systems have lead times of many months, hence it is necessary to order such systems with long-term framework-orders to ensure the demands from the market are covered. The aggregate purchase commitments over the next twelve months are approximately $2.8 million.

Contingencies

On March 11, 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID-19”) as a global pandemic, which continues to spread throughout the United States and around the world.

As a result, we have experienced a material impact on our business, financial condition or results of operations for the nine months ended September 30, 2020 and significant business disruptions as a result of the outbreak. For example, most of our employees in the U.S. are currently working remotely from home, we have suspended virtually all business travel, and we are mostly unable to physically meet with future and current customers to sell and market our products. In addition, the COVID-19 pandemic has interrupted many of our clinical activities, which might delay our ability to complete clinical trials and obtain regulatory approval for new products including FDA clearance of our Acuitas AMR Gene Panel (Isolate) product.

We continue to monitor the impacts of COVID-19 on the global economy and on our business operations. However, at this time, it is difficult to predict how long the potential operational impacts of COVID-19 will remain in effect or to what degree they will impact our operations and financial results. An extended period of global supply chain and economic disruption could materially affect our business, results of operations, access to sources of liquidity and financial condition, as well as our ability to execute our business strategies and initiatives in their respective expected time frames. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.

Summary of significant accounting policies (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

	September 30, 2020		December 31, 2019		September 30, 2019		December 31, 2018
Cash and cash equivalents	$	10,488,072	$	2,708,223	$	626,420	$	4,572,487
Restricted cash		293,972		185,380		185,380		164,720
Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows	$	10,782,044	$	2,893,603	$	811,800	$	4,737,207

Schedule of Inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	September 30, 2020		December 31, 2019
Raw materials and supplies	$	780,054	$	315,542
Work-in-process		141,365		35,080
Finished goods		2,053,641		122,408
Total	$	2,975,060	$	473,030

Schedule of Finite-Lived Intangible Assets

					September 30, 2020										December 31, 2019
	Subsidiary		Cost		Accumulated Amortization			Impairment			Effect of foreign exchange rates		Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames		AdvanDx	$	461,000	$	(217,413	)	$	(243,587	)		—	$	—	$	(205,887	)	$	255,113
Developed technology		AdvanDx		458,000		(308,526	)		(149,474	)		—		—		(292,170	)		165,830
Customer relationships		AdvanDx		1,094,000		(736,465	)		(357,535	)		—		—		(697,393	)		396,607
Trademarks and tradenames		Curetis		1,768,000		(93,606	)		—			104,096		1,778,490		—			—
Distributor relationships		Curetis		2,362,000		(83,370	)		—			139,067		2,417,697		—			—
A50 - Developed technology		Curetis		377,000		(28,514	)		—			22,197		370,683		—			—
Ares - Developed technology		Curetis		5,345,000		(202,132	)		—			314,697		5,457,565		—			—
A30 - In-Process Research & Development		Curetis		5,711,000		—			—			336,245		6,047,245		—			—
			$	17,576,000	$	(1,670,026	)	$	(750,596	)	$	916,302	$	16,071,680	$	(1,195,450	)	$	817,550

Schedule of Estimated Useful Lives of Identifiable Intangible Assets

Identifiable intangible assets will be amortized on a straight-line basis over their estimated useful lives. The estimated useful lives of the intangibles are:

		Estimated Useful Life
Trademarks and tradenames		10 years
Customer/distributor relationships		15 years
A50 – Developed technology		7 years
Ares – Developed technology		14 years
A30 – Acquired in-process research & development		Indefinite

Schedule of Expected Amortization of Intangible Assets

Year Ending December 31,
2020 (Three months)	$	203,811
2021		815,242
2022		815,242
2023		815,242
2024		815,242
2025		815,242
Thereafter		5,744,414
Total	$	10,024,435

Schedule of Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill as of September 30, 2020, and since December 31, 2019, were as follows:

Balance as of December 31, 2019	$	600,814
Acquisition of Curetis		7,046,535
Changes in currency translation		410,545
Balance as of September 30, 2020	$	8,057,894

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue
Total revenue	$ 1,056,765	$ 648,220	$ 2,862,083	$ 2,677,940
Operating expenses
Research and development	2,433,553	1,139,369	6,630,134	4,069,335
General and administrative	2,356,413	1,560,706	6,549,432	4,901,136
Sales and marketing	932,671	376,955	2,258,980	1,142,755
Transaction costs		538,061	470,322	538,061
Impairment of right-of-use asset				520,759
Impairment of intangibles assets			750,596
Total operating expenses	7,232,727	4,073,648	19,550,345	12,446,261
Operating loss	(6,175,962)	(3,425,428)	(16,688,262)	(9,768,321)
Other income (expense)
Interest and other income (expense)	19,965	1,043	101,644	(8,213)
Interest expense	(1,183,927)	(49,099)	(2,267,085)	(142,672)
Foreign currency transaction losses	(501,168)	(8,954)	(794,832)	(9,426)
Change in fair value of derivative financial instruments	165,497		548,008	67
Total other income (expense)	(1,499,633)	(57,010)	(2,412,265)	(160,244)
Loss before income taxes	(7,675,595)	(3,482,438)	(19,100,527)	(9,928,565)
Provision for income taxes
Net loss	(7,675,595)	(3,482,438)	(19,100,527)	(9,928,565)
Net loss available to common stockholders	$ (7,675,595)	$ (3,482,438)	$ (19,100,527)	$ (9,928,565)
Net loss per common share - basic and diluted	$ (0.40)	$ (3.95)	$ (1.36)	$ (13.32)
Weighted average shares outstanding - basic and diluted	19,116,864	882,280	14,016,896	745,471
Net loss	$ (7,675,595)	$ (3,482,438)	$ (19,100,527)	$ (9,928,565)
Other comprehensive income - foreign currency translation	1,266,901	7,298	1,631,319	5,174
Comprehensive loss	(6,408,694)	(3,475,140)	(17,469,208)	(9,923,391)
Product sales [Member]
Revenue
Total revenue	601,562	573,035	1,569,799	1,597,505
Operating expenses
Cost of products and services	1,350,296	262,373	2,340,766	681,568
Service [Member]
Revenue
Total revenue	112,892	185	138,884	5,435
Operating expenses
Cost of products and services	159,794	196,184	550,115	592,647
Collaborations Revenue [Member]
Revenue
Total revenue	$ 342,311	$ 75,000	$ 1,153,400	$ 1,075,000

Leases (Schedule of Supplemental Cash Flow Information) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash used in operating activities
Operating leases	$ 882,659	$ 655,963
Finance leases	45,185	60,482
Cash used in financing activities
Finance leases	467,592	389,501
ROU assets obtained in exchange for lease obligations
Finance leases		$ 592,014

Related party transactions

9 Months Ended

Sep. 30, 2020

Related party transactions

Note 12 – Related party transactions

Prior to his departure from the Company’s Board on September 30, 2019, Dr. David Rubin served as a representative of Merck Global Health Innovation Fund, or MGHIF, an affiliate of Merck, Inc. The Company has the following relationships with Merck and its subsidiaries:

On June 11, 2018, the Company executed the Allonge to its Second Amended and Restated Senior Secured Promissory Note, dated June 28, 2017, with a principal amount of $1,000,000 issued to MGHIF. The Allonge provided that accrued and unpaid interest of $285,512 due as of July 14, 2018, the original maturity date, be paid through the issuance of shares of OpGen’s common stock in a private placement transaction. In addition, the Allonge revised and extended the maturity date for payment of the MGHIF Note to six semi-annual payments of $166,667 plus accrued and unpaid interest beginning on January 2, 2019 and ending on July 1, 2021. On July 30, 2018, the Company issued 7,212 shares of common stock to MGHIF in a private placement transaction for $285,512 of accrued and unpaid interest due as of July 14, 2018 under the MGHIF Note.

On April 1, 2020, as part of the Transaction, Oliver Schacht, Ph.D., the former CEO of Curetis N.V., was appointed as the CEO of the Company, and Johannes Bacher the former COO of Curetis N.V. was appointed as the COO of the Company. Effective April 1, 2020, Mr. Schacht and Mr. Bacher were appointed as liquidators of Curetis N.V. in liquidation and Curetis GmbH was designated as Custodian of the Books for Curetis N.V. During a portion of the nine months ended September 30, 2020, Curetis N.V. in liquidation processed payroll for Mr. Schacht and Mr. Bacher and invoiced OpGen and Curetis GmbH, respectively, in line with their signed management agreements.

Related party transactions (Details) - Second Amended and Restated Senior Secured Promissory Note [Member] - MGHIF [Member] - USD ($)	Jan. 02, 2019	Jul. 14, 2018	Jun. 11, 2018
Related Party Transaction [Line Items]
Principal amount			$ 1,000,000
Accrued and unpaid interest		$ 285,512
Semi annual payments	$ 166,667
Common shares issued for debt		7,212
Common shares issued for debt, value		$ 285,512

Leases (Tables)

9 Months Ended

Sep. 30, 2020

Leases [Abstract]

Schedule of ROU Assets and Lease Liabilities

The following table presents the Company’s ROU assets and lease liabilities as of September 30, 2020 and December 31, 2019:

Lease Classification	September 30, 2020		December 31, 2019
ROU Assets:
Operating	$	1,373,418	$	1,043,537
Financing		571,329		958,590
Total ROU assets	$	1,944,747	$	2,002,127
Liabilities
Current:
Operating	$	1,142,435	$	1,017,414
Finance		348,000		579,030
Noncurrent:
Operating		554,295		547,225
Finance		76,701		313,263
Total lease liabilities	$	2,121,431	$	2,456,932

Schedule of Maturities of Lease Liabilities

Maturities of lease liabilities as of September 30, 2020 by fiscal year are as follows:

Maturity of Lease Liabilities		Operating			Finance			Total
	2020	$	413,498		$	120,352		$	533,850
	2021		953,714			281,914			1,235,628
	2022		205,389			45,374			250,763
	2023		75,533			3,364			78,897
	2024		75,533			280			75,813
	Thereafter		44,061			—			44,061
	Total lease payments		1,767,728			451,284			2,219,012
	Less: Interest		(70,998	)		(26,583	)		(97,581	)
	Present value of lease liabilities	$	1,696,730		$	424,701		$	2,121,431

Schedule of Statement of Operations Classification of Lease Costs and Other Information

Statement of operations classification of lease costs as of the three and nine months ended September 30, 2020, and 2019 are as follows:

		Three months ended September 30,				Nine months ended September 30,
Lease Cost	Classification	2020		2019		2020		2019
Operating	Operating expenses	$	332,241	$	216,368	$	882,659	$	655,963
Finance:
Amortization	Operating expenses		125,005		124,749		387,262		329,438
Interest expense	Other expenses		15,806		18,704		49,326		60,482
Total lease costs		$	473,052	$	359,821	$	1,319,247	$	1,045,883

Other lease information as of September 30, 2020 is as follows:

Other Information	Total
Weighted average remaining lease term (in years)
Operating leases		2.0
Finance leases		1.1
Weighted average discount rate:
Operating leases		5.9	%
Finance leases		9.7	%

Schedule of Supplemental Cash Flow Information

Supplemental cash flow information as of the nine months ended September 30, 2020, and 2019 is as follows:

Supplemental Cash Flow Information	2020		2019
Cash paid for amounts included in the measurement of lease liabilities
Cash used in operating activities
Operating leases	$	882,659	$	655,963
Finance leases	$	45,185	$	60,482
Cash used in financing activities
Finance leases	$	467,593	$	389,501
ROU assets obtained in exchange for lease obligations:
Finance leases	$	—	$	592,014

Liquidity and management's plans

9 Months Ended

Sep. 30, 2020

Liquidation Basis Of Accounting Abstract [Abstract]

Liquidity and management's plans

Note 2 – Liquidity and management’s plans

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing transactions, including the following in 2019 and 2020 to date:

On February 11, 2020, the Company entered into an At the Market Common Offering (the "ATM Agreement") with H.C. Wainwright ?char_error? Co., LLC ("Wainwright"), which we amended and restated on November 13, 2020 to add BTIG, LLC ("BTIG"), pursuant to which the Company may offer and sell from time to time in an "at the market offering," at its option, up to an aggregate of $22.1 million of shares of the Company's common stock through the sales agents, (the "2020 ATM Offering"). During the three months ended September 30, 2020, the Company sold 1,523,663 shares of its common stock under the 2020 ATM Offering resulting in aggregate net proceeds to the Company of approximately $3.6 million, and gross proceeds of $3.8 million. During the nine months ended September 30, 2020, the Company sold 7,078,039 shares of its common stock under the 2020 ATM Offering resulting in aggregate net proceeds to the Company of approximately $15.0 million, and gross proceeds of $15.7 million.

On October 28, 2019, the Company closed a public offering (the “October 2019 Public Offering”) of 2,590,170 units at $2.00 per unit and 2,109,830 pre-funded units at $1.99 per pre-funded unit, raising gross proceeds of approximately $9.4 million and net proceeds of approximately $8.3 million. Each unit included one share of common stock and one common warrant to purchase one share of common stock at an exercise price of $2.00 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase one share of common stock at an exercise price of $2.00 per share. The common warrants are exercisable immediately and have a five-year term from the date of issuance. As of September 30, 2020, all 2,109,830 pre-funded warrants issued in the October 2019 Public Offering have been exercised. Additionally, during the nine months ended September 30, 2020, 4,341,000 common warrants issued in the October 2019 Public Offering were exercised for net proceeds of approximately $8.7 million. As of September 30, 2020, 359,000 common warrants issued in the October 2019 Public Offering remain outstanding.

On March 29, 2019, the Company closed a public offering (the “March 2019 Public Offering”) of 450,000 shares of its common stock at a public offering price of $12.00 per share. The offering raised gross proceeds of $5.4 million and net proceeds of approximately $4.8 million.

To meet our capital needs, the Company is considering multiple alternatives, including, but not limited to, strategic financings or other transactions, additional equity financings, debt financings and other funding transactions, licensing and/or partnering arrangements. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The Company believes that current cash will be sufficient to fund operations into the first quarter of 2021. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during or before the end of the first quarter of 2021, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances, the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until we are able to obtain sufficient financing. If sufficient financing is not received on a timely basis, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.

Business Combination

9 Months Ended

Sep. 30, 2020

Business Combinations [Abstract]

Business Combination

Note 4 – Business Combination

On April 1, 2020, the Company completed its business combination transaction with Curetis N.V., a public company with limited liability under the laws of the Netherlands, as contemplated by the Implementation Agreement, dated as of September 4, 2019, by and among the Company, the Seller, and Crystal GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany and wholly-owned subsidiary of the Company. Pursuant to the Implementation Agreement, the Purchaser acquired all of the shares of Curetis GmbH, a private limited liability company organized under the laws of the Federal Republic of Germany, and certain other assets and liabilities of the Seller, as further described below, and paid, as the sole consideration, 2,028,208 shares of the Company’s common stock, to the Seller, and reserved for future issuance (a) 134,356 shares of Common Stock, in connection with its assumption of the Seller’s 2016 Stock Option Plan, as amended (the “Seller Stock Option Plan”), and the outstanding awards thereunder, and (b) 500,000 shares of common stock to be issued upon the conversion, if any, of certain convertible notes issued by the Seller.

At the closing, the Company assumed all of the liabilities of the Seller solely and exclusively related to the acquired business, which is providing innovative solutions, through development of proprietary platforms, diagnostic content, applied bioinformatics, lab services, research services and commercial collaborations and agreements, for molecular microbiology, diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients. Pursuant to the Implementation Agreement, the Company also assumed and adopted the Seller Stock Option Plan as an Amended and Restated Stock Option Plan of the Company. In connection with the foregoing, the Company assumed all awards thereunder that were outstanding as of the Closing Date and converted such awards into options to purchase shares of the Company’s Common Stock pursuant to the terms of the applicable award. In addition, the Company assumed, at the closing, all of the outstanding convertible notes issued by Seller in favor of YA II PN, LTD, pursuant to the previously disclosed Assignment of the Agreement for the Issuance of and Subscription to Notes Convertible into Shares, dated February 24, 2020, and entered into pursuant to the Implementation Agreement.

Curetis’ assets and liabilities were measured and recognized at their fair values as of the transaction date and combined with the assets, liabilities and results of operations of OpGen after the consummation of the business combination. The allocation of the purchase price to acquired assets and assumed liabilities based on their underlying fair values requires the extensive use of significant estimates and management’s judgment. The allocation of the purchase price is preliminary at this time, and will remain as such until management completes valuations and other studies in order to finalize the valuation of the net assets acquired. These provisional estimates will be adjusted upon the availability of further information regarding events or circumstances which exist at the acquisition date and such adjustments may be significant.

The components of the purchase price and net assets acquired are as follows:

Purchase Price

Number of shares issued to Curetis N.V		2,028,208
Multiplied by the market value per share of OpGen's common stock (i)	$	2.39
Total fair value of common stock issued to Curetis N.V shareholders		4,847,417
Fair value of replacement stock awards related to precombination service (ii)		136,912
Fair value of convertible notes assumed (iii)		1,323,750
Fair value of EIB debt assumed (iv)		15,784,892
Funds advanced to Curetis GmbH under Interim Facility		4,808,712
Cash, cash equivalents, and restricted cash acquired		(1,266,849	)
	$	25,634,834

(i)

The price per share of OpGen’s common stock was based on the closing price as reported on the Nasdaq Capital Market on April 1, 2020.

(ii)

The fair value of the stock options assumed was determined using the Black-Scholes option pricing model.

(iii)

(iv)

The fair value of the EIB debt is determined using a discounted cash flow analysis with current applicable rates for similar instruments.

Net Assets Acquired

Assets acquired
Receivables	$	482,876
Inventory		2,022,577
Property and equipment		3,802,431
Right of use assets		1,090,812
Other current assets		585,500
Finite-lived intangible assets
Trade names/trademarks		1,768,000
Customer/distributor relationships		2,362,000
A50 - Developed technology		377,000
Ares - Developed technology		5,345,000
Indefinite-lived intangible assets
A30 - In-process research & development		5,711,000
Goodwill		7,046,535
Liabilities assumed
Accounts payable		(1,168,839	)
Accrued expenses and other current liabilities		(2,016,946	)
Derivative liabilities		(615,831	)
Lease liabilities		(1,108,193	)
Other long-term liabilities		(49,088	)
Net assets acquired	$	25,634,834

The fair value of identifiable intangible assets has been determined using the income approach, which involves significant unobservable inputs (Level 3 inputs). These inputs include projected sales, margin, required rate of return and tax rate, as well as an estimated royalty rate in the case of the trade names/trademarks intangibles. The trade names/trademarks intangibles are valued using a relief-from-royalty method. The customer/distributor relationships are valued using the with and without method. The developed technology intangibles are valued using a multi-period earnings method.

The Company determined the fair value of an IPR&D asset resulting from the acquisition of Curetis using the multi-period earnings method under the income approach. This method reflects the present value of the projected cash flows that are expected to be generated by the IPR&D, less charges representing the required return on other assets to sustain those cash flows.

The weighted-average amortization periods for finite-lived intangible assets acquired are 15 years for customer/distributor relationships, 10 years for developed technology and 10 years for trade names/trademarks.

The total consideration paid in the acquisition exceeded the estimated fair value of the tangible and identifiable intangible assets acquired and liabilities assumed, resulting in approximately $7.0 million of goodwill. Goodwill, primarily related to expected synergies gained from combining operations, sales growth from future product offerings and customers, together with certain intangible assets that do not qualify for separate recognition, including assembled workforce, is not tax deductible in all relevant taxing jurisdictions.

Unaudited pro forma results	Three months ended September 30,			Nine months ended September 30,
	2019			2020			2019
Revenues	$	982,506		$	3,886,834		$	4,245,120
Net loss		(9,204,658	)		(22,340,822	)		(27,067,942	)
Net loss per share		(10.43	)		(1.59	)		(36.31	)

License agreements, research collaborations and development agreements (Details) - USD ($)		3 Months Ended		9 Months Ended
	Jul. 13, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract		$ 1,056,765	$ 648,220	$ 2,862,083	$ 2,677,940
Royalty expense		62,500	62,500	187,500	187,500
Annual future minimum royalty payments due		$ 250,000		250,000
Settlement fee				$ 350,000
Royalty percentage on sale of products		10.00%		10.00%
Collaborations Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract		$ 342,311	75,000	$ 1,153,400	1,075,000
Global leading IVD corporation [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Contractual agreement period				10 months
Revenue from contract		351,000		$ 816,000
Option fees received	$ 1,200,000			550,000
New York State Department of Health and ILUM Health Solutions, LLC [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Collaboration revenue receivable over 12 months of the project		1,600,000		$ 1,600,000
Contractual agreement period				15 months
New York State Department of Health and ILUM Health Solutions, LLC [Member] \| Collaborations Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract		43,000	$ 75,000	$ 323,000	$ 1,075,000
OpGen [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Contract value		$ 450,000		$ 450,000
Qiagen [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Contractual agreement period				20 years

Fair value measurements (Narrative) (Details)	1 Months Ended	9 Months Ended
Fair value measurements (Narrative) (Details)	Jun. 30, 2019 EUR (€)	Sep. 30, 2020 USD ($)
Fair Value on Non-Recurring Basis [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of non-financial assets and liabilities at fair value \| $		$ 750,596
Fair Value on Recurring Basis [Member] \| Curetis GmbH [Member] \| European Investment Bank [Member] \| Share-based Payment Arrangement, Tranche One [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Drew down amount	€ 5,000,000
Participation percentage interest	2.10%
Additional payment percentage	2.10%
Fair Value on Recurring Basis [Member] \| Curetis GmbH [Member] \| European Investment Bank [Member] \| Share-based Payment Arrangement, Tranche One [Member] \| Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cumulative equity capital raised	€ 15,000,000
Fair Value on Recurring Basis [Member] \| OpGen's Equity [Member] \| European Investment Bank [Member] \| Share-based Payment Arrangement, Tranche One [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Participation percentage interest	0.30%
Maturity period	mid-2024 and mid-2025

Liquidity and Management's Plans (Details) - USD ($)		1 Months Ended		3 Months Ended			9 Months Ended
Liquidity and Management's Plans (Details) - USD ($)	Mar. 29, 2019	Sep. 30, 2020	Oct. 28, 2019	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Feb. 11, 2020
Conversion of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs							$ 14,982,663	$ 4,782,509
October 2019 Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues			2,590,170
Shares issued, price per share			$ 2.00
Each unit includes number of common shares apart from warrants			1
Each unit includes number of common stock warrants apart from common stock			1
Each prefunded unit included number prefunded warrants apart from common stock warrants			1
Each prefunded unit included number common stock warrants apart from prefunded warrants			1
Sale of stock, description of transaction			Each unit included one share of common stock and one common warrant to purchase one share of common stock at an exercise price of $2.00 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase one share of common stock at an exercise price of $2.00 per share.
Class of warrant or right, exercise price of warrants or rights			$ 2.00
Warrants exercisable period			5 years
Pre-funded Units [Member] \| October 2019 Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues			2,109,830
Shares issued, price per share			$ 1.99
Gross proceeds from sale of common stock and warrants			$ 9,400,000
Net proceeds from sale of common stock and warrants			$ 8,300,000
Class of warrant or right, exercise price of warrants or rights			$ 0.01
Warrants exercised		2,109,830
Common Stock [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues				1,523,663	2,739,442	2,814,934
Common Stock [Member] \| October 2019 Public Offering [Member]
Conversion of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs							8,700,000
Common Stock [Member] \| March 2019 Public Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues	450,000
Shares issued, price per share	$ 12.00
Gross proceeds from sale of common stock	$ 5,400,000
Proceeds from issuance of common stock, net of issuance costs	$ 4,800,000
Common Warrants [Member] \| October 2019 Public Offering [Member]
Conversion of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs							$ 8,100,000
Warrants exercised		359,000					4,341,000
H.C. Wainwright & Co., LLC [Member] \| Common Stock [Member] \| 2020 ATM Offering [Member]
Conversion of Stock [Line Items]
Stock issued during period, shares, new issues				1,523,663			7,078,039
Gross proceeds from sale of common stock				$ 3,800,000			$ 15,700,000
Proceeds from issuance of common stock, net of issuance costs				$ 3,600,000			$ 15,000,000
H.C. Wainwright & Co., LLC [Member] \| Common Stock [Member] \| 2020 ATM Offering [Member] \| Maximum [Member]
Conversion of Stock [Line Items]
Common shares available for future issuance amount									$ 22,100,000

Leases (Schedule of Other Information) (Details)	Sep. 30, 2020
Weighted average remaining lease term (in years)
Operating leases	2 years
Finance leases	1 year 1 month 6 days
Weighted average discount rate:
Operating leases	5.90%
Finance leases	9.70%

Stockholders' equity (Tables)

9 Months Ended

Sep. 30, 2020

Stockholders' Equity Note [Abstract]

Schedule of Company Recognized Stock-Based Compensation Expense

For the three and nine months ended September 30, 2020 and 2019, the Company recognized share-based compensation expense as follows:

	Three months ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Cost of services	$	736	$	584	$	2,191	$	1,146
Research and development		12,259		20,175		38,322		55,635
General and administrative		24,100		65,318		102,810		202,696
Sales and marketing		4,608		5,090		11,707		15,694
	$	41,703	$	91,167	$	155,030	$	275,171

Schedule of Warrants to Purchase Shares of Common Stock

At September 30, 2020 and December 31, 2019, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at
Issuance		Exercise Price	Expiration	September 30, 2020	December 31, 2019
January 2010	$	3,955.00	January 2020	—	17
March 2010	$	3,955.00	March 2020	—	7
November 2011	$	3,955.00	November 2021	15	15
December 2011	$	3,955.00	December 2021	2	2
February 2015	$	3,300.00	February 2025	451	451
May 2015	$	3,300.00	May 2020	—	6,697
May 2016	$	656.20	May 2021	9,483	9,483
June 2016	$	656.20	May 2021	4,102	4,102
June 2017	$	390.00	June 2022	938	938
July 2017	$	345.00	July 2022	318	318
July 2017	$	250.00	July 2022	2,501	2,501
July 2017	$	212.60	July 2022	50,006	50,006
February 2018	$	81.25	February 2023	9,232	9,232
February 2018	$	65.00	February 2023	92,338	92,338
October 2019	$	2.00	October 2024	359,000	4,700,000
October 2019	$	2.60	October 2024	235,000	235,000
				763,386	5,111,107

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net loss	$ (19,100,527)	$ (9,928,565)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	1,622,922	687,107
Noncash interest expense	1,714,543	2,659
Noncash interest income	(87,233)
Stock compensation expense	155,030	275,171
Loss on sale of equipment		9,904
Change in fair value of derivative liabilities	(548,008)	(67)
Impairment of right-of-use asset		520,759
Impairment of intangible assets	750,596
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	649,079	(5,173)
Inventory	(348,484)	74,449
Other assets	754,484	55,122
Accounts payable	(1,037,810)	314,559
Accrued compensation and other liabilities	(166,753)	(55,871)
Deferred revenue	(816,006)	(6,016)
Net cash used in operating activities	(16,458,167)	(8,055,962)
Cash flows from investing activities
Acquisition of business, net of cash acquired of $1,266,849	1,266,849
Note receivable	(2,200,000)
Purchases of property and equipment	(2,455)	(72,607)
Proceeds from sale of equipment		29,250
Net cash used in investing activities	(935,606)	(43,357)
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs	14,982,663	4,782,509
Proceeds from the exercise of common stock warrants	8,682,000
Proceeds from debt	1,871,308	470,519
Payments on debt	(853,063)	(694,156)
Payments on finance lease obligations	(467,592)	(389,501)
Net cash provided by financing activities	24,215,316	4,169,371
Effects of exchange rates on cash	1,066,898	4,541
Net increase (decrease) in cash, cash equivalents and restricted cash	7,888,441	(3,925,407)
Cash, cash equivalents and restricted cash at beginning of period	2,893,603	4,737,207
Cash, cash equivalents and restricted cash at end of period	10,782,044	811,800
Supplemental disclosure of cash flow information
Cash paid for interest	118,540	170,608
Supplemental disclosures of noncash investing and financing activities:
Right-of-use assets acquired through finance leases		528,413
Conversion of accounts payable to finance lease		63,600
Shares issued in business combination	4,847,417
Shares issued to settle convertible notes	$ 1,450,797

Business Combination (Schedule of Unaudited Pro Forma Results) (Details) - Curetis N.V [Member] - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Business Acquisition [Line Items]
Revenues	$ 982,506	$ 3,886,834	$ 4,245,120
Net loss	$ (9,204,658)	$ (22,340,822)	$ (27,067,942)
Net loss per share	$ (10.43)	$ (1.59)	$ (36.31)

Summary of significant accounting policies (Schedule of Inventories) (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Inventories
Raw materials and supplies	$ 780,054	$ 315,542
Work-in-process	141,365	35,080
Finished goods	2,053,641	122,408
Total	$ 2,975,060	$ 473,030

Revenue from contracts with customers (Schedule of Revenues by Type of Service) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,056,765	$ 648,220	$ 2,862,083	$ 2,677,940
Product sales [Member]
Disaggregation of Revenue [Line Items]
Total revenue	601,562	573,035	1,569,799	1,597,505
Service [Member]
Disaggregation of Revenue [Line Items]
Total revenue	112,892	185	138,884	5,435
Collaborations Revenue [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 342,311	$ 75,000	$ 1,153,400	$ 1,075,000

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Summary of significant accounting policies (Schedule of Changes in Carrying Amount of Goodwill) (Details)	9 Months Ended
	Sep. 30, 2020 USD ($)
Accounting Policies [Abstract]
Balance as of December 31, 2019	$ 600,814
Acquisition of Curetis	7,046,535
Changes in currency translation	410,545
Balance as of September 30, 2020	$ 8,057,894

Stockholders' equity (Company Recognized Stock-Based Compensation Expense) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 41,703	$ 91,167	$ 155,030	$ 275,171
Cost of Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	736	584	2,191	1,146
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	12,259	20,175	38,322	55,635
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	24,100	65,318	102,810	202,696
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 4,608	$ 5,090	$ 11,707	$ 15,694

Subsequent Events (Details) - USD ($)		9 Months Ended
Subsequent Events (Details) - USD ($)	Nov. 10, 2020	Sep. 30, 2020
Subsequent Event [Member]
Subsequent Event [Line Items]
Base rent under the new facility lease agreement	$ 333,300
Lease term	10 years
Escalating annual percentageof base rent	2.75%
2020 ATM Offering [Member]
Subsequent Event [Line Items]
Number of shares sold		355,691
Number of shares sold, value		$ 756,000
Number of shares sold, value net		$ 782,000

Summary of significant accounting policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Summary of significant accounting policies

Note 3 – Summary of significant accounting policies

Basis of presentation and consolidation

Foreign currency

Use of estimates

Fair value of financial instruments

Cash, cash equivalents and restricted cash

	September 30, 2020		December 31, 2019		September 30, 2019		December 31, 2018
Cash and cash equivalents	$	10,488,072	$	2,708,223	$	626,420	$	4,572,487
Restricted cash		293,972		185,380		185,380		164,720
Total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows	$	10,782,044	$	2,893,603	$	811,800	$	4,737,207

Accounts receivable

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	September 30, 2020		December 31, 2019
Raw materials and supplies	$	780,054	$	315,542
Work-in-process		141,365		35,080
Finished goods		2,053,641		122,408
Total	$	2,975,060	$	473,030

Long-lived assets

Property and equipment

Leases

ROU Assets

Intangible assets and goodwill

Intangible assets and goodwill as of September 30, 2020 consist of finite-lived and indefinite-lived intangible assets and goodwill.

Finite-lived and indefinite-lived intangible assets

					September 30, 2020										December 31, 2019
	Subsidiary		Cost		Accumulated Amortization			Impairment			Effect of foreign exchange rates		Net Balance		Accumulated Amortization			Net Balance
Trademarks and tradenames		AdvanDx	$	461,000	$	(217,413	)	$	(243,587	)		—	$	—	$	(205,887	)	$	255,113
Developed technology		AdvanDx		458,000		(308,526	)		(149,474	)		—		—		(292,170	)		165,830
Customer relationships		AdvanDx		1,094,000		(736,465	)		(357,535	)		—		—		(697,393	)		396,607
Trademarks and tradenames		Curetis		1,768,000		(93,606	)		—			104,096		1,778,490		—			—
Distributor relationships		Curetis		2,362,000		(83,370	)		—			139,067		2,417,697		—			—
A50 - Developed technology		Curetis		377,000		(28,514	)		—			22,197		370,683		—			—
Ares - Developed technology		Curetis		5,345,000		(202,132	)		—			314,697		5,457,565		—			—
A30 - In-Process Research & Development		Curetis		5,711,000		—			—			336,245		6,047,245		—			—
			$	17,576,000	$	(1,670,026	)	$	(750,596	)	$	916,302	$	16,071,680	$	(1,195,450	)	$	817,550

Identifiable intangible assets will be amortized on a straight-line basis over their estimated useful lives. The estimated useful lives of the intangibles are:

		Estimated Useful Life
Trademarks and tradenames		10 years
Customer/distributor relationships		15 years
A50 – Developed technology		7 years
Ares – Developed technology		14 years
A30 – Acquired in-process research & development		Indefinite

The Company reviews the useful lives of intangible assets when events or changes in circumstances occur which may potentially impact the estimated useful life of the intangible assets.

Year Ending December 31,
2020 (Three months)	$	203,811
2021		815,242
2022		815,242
2023		815,242
2024		815,242
2025		815,242
Thereafter		5,744,414
Total	$	10,024,435

Goodwill

The changes in the carrying amount of goodwill as of September 30, 2020, and since December 31, 2019, were as follows:

Balance as of December 31, 2019	$	600,814
Acquisition of Curetis		7,046,535
Changes in currency translation		410,545
Balance as of September 30, 2020	$	8,057,894

Revenue recognition

Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.

Research and development costs

Stock-based compensation

Income taxes

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

Adopted accounting pronouncements

The Company adopted this guidance effective January 1, 2019 using the modified retrospective transition method and the following practical expedients:

The Company did not reassess if any expired or existing contracts are or contain leases.

The Company did not reassess the classification of any expired or existing leases.

Recently issued accounting standards

Business Combination (Narrative) (Details)	9 Months Ended
Business Combination (Narrative) (Details)	Sep. 30, 2020 USD ($) shares
Customer/distributor relationships [Member]
Business Acquisition [Line Items]
Weighted-average amortization periods for finite-lived intangible assets acquired	15 years
Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Weighted-average amortization periods for finite-lived intangible assets acquired	10 years
Curetis N.V [Member] \| Customer/distributor relationships [Member]
Business Acquisition [Line Items]
Weighted-average amortization periods for finite-lived intangible assets acquired	15 years
Curetis N.V [Member] \| Developed Technology [Member]
Business Acquisition [Line Items]
Weighted-average amortization periods for finite-lived intangible assets acquired	10 years
Curetis N.V [Member] \| Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Weighted-average amortization periods for finite-lived intangible assets acquired	10 years
Curetis N.V [Member] \| 2016 Stock Option Plan [Member]
Business Acquisition [Line Items]
Common stock reserved for future issuance \| shares	134,356
Common stock to be issued upon conversion \| $	$ 500,000

Summary of significant accounting policies (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Jan. 02, 2019
Significant Accounting Policies [Line Items]
FDIC limit of insurable cash	$ 250,000		$ 250,000
Letters of credit outstanding, amount	293,972		293,972		$ 185,380
Allowance for doubtful accounts receivable	20,753		20,753		20,753
Inventory valuation reserves	412,827		412,827		92,454
Amortization of intangible assets	205,026	$ 66,954	464,689	$ 200,862
Impairment of finite-lived intangible assets			750,596
Goodwill	8,057,894		8,057,894		600,814
Finite-lived intangible assets, fair value	0		$ 0
Antidilutive securities excluded from computation of earnings per share, amount			2,200,000	200,000
Operating lease right of use asset	1,373,418		$ 1,373,418		1,043,537	$ 2,200,000
Operating lease liability	$ 1,696,730		$ 1,696,730			$ 2,500,000
Minimum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due			30 days
Maximum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due			60 days
Domestic Country [Member]
Significant Accounting Policies [Line Items]
Operating loss carryforwards					$ 188,282,298
Operating loss carryforwards, expiration terms			begin to expire in 2022
Customer One [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			17.00%		44.00%
Customer One [Member] \| Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage	33.00%	12.00%	29.00%	40.00%
Customer Two [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			10.00%
Customer Two [Member] \| Sales Revenue, Net [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			11.00%
ASU 2016-02 [Member]
Significant Accounting Policies [Line Items]
Impairment charge				$ 520,759

Revenue from contracts with customers

9 Months Ended

Sep. 30, 2020

Revenue from Contract with Customer [Abstract]

Revenue from contracts with customers

Note 5 – Revenue from contracts with customers

Disaggregated revenue

	Three Months Ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Product sales	$	601,562	$	573,035	$	1,569,799	$	1,597,505
Laboratory services		112,892		185		138,884		5,435
Collaboration revenue		342,311		75,000		1,153,400		1,075,000
Total revenue	$	1,056,765	$	648,220	$	2,862,083	$	2,677,940

Revenues by geography are as follows:

	Three Months Ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Domestic	$	309,119	$	597,997	$	1,202,244	$	2,539,519
International		747,646		50,223		1,659,839		138,421
Total revenue	$	1,056,765	$	648,220	$	2,862,083	$	2,677,940

Deferred revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2019	$	9,808
Acquired deferrals from Curetis, net of amounts recognized in the current period		13,270
Revenue recognized in the current period from the amounts in the beginning balance		—
Effect of foreign exchange rates		28,544
Balance at September 30, 2020	$	51,622

Contract assets

The Company had approximately $22,000 of contract assets as of September 30, 2020, which are generated when contractual billing schedules differ from revenue recognition timing. The Company had no contract assets as of December 31, 2019. Contract assets represent a conditional right to consideration for satisfied performance obligations that becomes a billed receivable when the conditions are satisfied.

Unsatisfied performance obligations

The Company had no unsatisfied performance obligations related to its contracts with customers at September 30, 2020 and December 31, 2019.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Revenue from contracts with customers (Schedule of Revenues by Geography) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,056,765	$ 648,220	$ 2,862,083	$ 2,677,940
Domestic [Member]
Disaggregation of Revenue [Line Items]
Total revenue	309,119	597,997	1,202,244	2,539,519
International [Member]
Disaggregation of Revenue [Line Items]
Total revenue	$ 747,646	$ 50,223	$ 1,659,839	$ 138,421

- Definition

+ References

+ Details